Drugs and the Kidney

  • William M. Bennett


Drug effects on the kidney and, in turn, the influence of renal disease on drug metabolism continue to play an important part of day-to-day clinical medicine for the nephrologist. This review updates current information in various areas of renal pharmacology emphasizing those recent advances with current or future clinical implications.


Renal Failure Peritoneal Dialysis Nephrotic Syndrome Acute Renal Failure Chronic Renal Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gibaldi, M., 1986, The basic concept: Clearance, J. Clin. Pharmacol. 26:330–331.PubMedGoogle Scholar
  2. 2.
    Pang, K.S., 1986, Metabolic first-pass effects, J. Clin. Pharmacol. 26:580–582.PubMedGoogle Scholar
  3. 3.
    Jordan, R.A. and Woolf, T.F., 1987, Basic concepts in drug metabolism: Part II, J. Clin. Pharmacol. 27:87–90.PubMedGoogle Scholar
  4. 4.
    Gregus, Z. and Klaassen, C.D., 1987, Biliary excretion, J. Clin. Pharmacol. 27:537–541.PubMedGoogle Scholar
  5. 5.
    Welling, P.G., 1986, Graphic methods in pharmacokinetics: The basics, J. Clin. Pharmacol. 26: 510–514.PubMedGoogle Scholar
  6. 6.
    Bayer, W.H., 1986, Therapeutic drug monitoring, West. J. Med. 145:524–527.PubMedGoogle Scholar
  7. 7.
    Sedman, A.J., Molitoris, B.A., Nakata, L.M., and Gal, J., 1986, Therapeutic drug monitoring in patients with chronic renal failure: Evaluation of the Abbott TDx™ drug assay system, Am. J. Nephrol. 6:132–134.PubMedGoogle Scholar
  8. 8.
    Worwag, E.M., Craig, R.M., Jansyn, E.M., Kirby, D., Hubler, G.L., and Atkinson, A. J, Jr., 1987, D-Xylose absorption and disposition in patients with moderately impaired renal function. Clin. Pharmacol. Ther. 41:351–357.PubMedGoogle Scholar
  9. 9.
    Balasa, R.W., Murray, R.L., Kondelis, N.P., and Bischel, M.D., 1987, Phosphate-binding properties and electrolyte content of aluminum hydroxide antacids, Nephron 45:16–21.PubMedGoogle Scholar
  10. 10.
    Gibson, T.P., 1986, Renal disease and drug metabolism: An overview, Am. J. Kidney Dis. 8:7–17.PubMedGoogle Scholar
  11. 11.
    Shear, N.H., Spielberg, S.P., Grant, D.M., Tang, B.K., and Kalow, W., 1986, Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity, Ann. Intern. Med. 105:179–184.PubMedGoogle Scholar
  12. 12.
    Siddoway, L.A., Thompson, K.A., McAllister, C.B., Wang, T., Wilkinson, G.R., Roden, D.M., and Woosley, R.L., 1987, Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences, Circulation 75:785–791.PubMedGoogle Scholar
  13. 13.
    Kelly, R.A., O’Hara, D.S., Mitch, W.E., Steinman, T.I., Goldszer, R.C., Solomon, H.S., and Smith, T.W., 1986, Endogenous digitalis-like factors in hypertension and chronic renal insufficiency, Kidney Int. 30:723–729.PubMedGoogle Scholar
  14. 14.
    Fitzsimmons, W.E., 1986, Influence of assay methodologies and interferences on the interpretation of digoxin concentrations, Drug Intell. Clin. Pharm. 20:538–542.PubMedGoogle Scholar
  15. 15.
    Vlasses, P.H., Besarab, A., Lottes, S.R., Conner, D.P., Green, P.J., and Gault, M.H., 1987, False-positive digoxin measurements due to conjugated metabolite accumulation in combined renal and hepatic dysfunction, Am. J. Nephrol. 7:355–359.PubMedGoogle Scholar
  16. 16.
    Walker, J.A., Bialy, G.B., Cronin Walker, V., Sherman, R.A., and Eisinger, R.P., 1987, Digoxin-like immunoreactive substance in chronic hemodialysis patients: Effect on digitoxin radioimmunoassay, Am. J. Nephrol. 7:300–302.PubMedGoogle Scholar
  17. 17.
    Gault, H., Vasdev, S., Vlasses, P., Longerich, L., and Dawe, M., 1986, Interpretation of serum digoxin values in renal failure, Clin. Pharmacol. Ther. 39:530–536.PubMedGoogle Scholar
  18. 18.
    Vasdev, S., Johnson, E., Longerich, L., Prabhakaran, V.M., and Gault, M.H., 1987, Plasma endogenous digitalis-like factor is in healthy individuals and in dialysis dependent and kidney transplant patients, Clin. Nephrol. 27:169–174.PubMedGoogle Scholar
  19. 19.
    Greenway, D.C. and Nanji, A.A., 1986, Digoxin-like immunoreactive substance in renal failure: A reappraisal, Nephron 44:108–110.PubMedGoogle Scholar
  20. 20.
    Greenblatt, D.J., Abernethy, D.R., and Shader, R.I., 1986, Pharmacokinetic aspects of drug therapy in the elderly, Ther. Drug. Monit. 8:249–255.PubMedGoogle Scholar
  21. 21.
    Cohen, J.L., 1986, Pharmacokinetic changes in aging, Am. J. Med. 80(Suppl 5A)31–38.PubMedGoogle Scholar
  22. 22.
    Brown, W.W., David, B.B., Spry, L.A., Wongsurawat, N., Malone, D., and Domoto, D.T., 1986, Aging and the kidney, Arch. Intern. Med. 146:1790–1796.PubMedGoogle Scholar
  23. 23.
    Keller, F., 1987, Kidney function and age. Nephrol. Dial. Transp. 2:382.Google Scholar
  24. 24.
    Drugs that cause psychiatric symptoms. 1986. The Medical Letter 28:81–86.Google Scholar
  25. 25.
    Williams, R.L., Thornhill, M.D., Upton, R.A., Blume, C., Clark, T.S., Lin, E., and Benet, L.Z., 1986, Absorption and disposition of two combination formulations of hydrochlorothiazide and triamterene: Influence of age and renal function, Clin. Pharmacol. Ther. 40:226–232.PubMedGoogle Scholar
  26. 26.
    Stemmer, C.L., Perez, G.O., and Oster, J.R., 1987, Impairment of p-2-Adrenoceptor-stimulated potassium uptake in end-stage renal disease, J. Clin. Pharmacol. 27:628–631.PubMedGoogle Scholar
  27. 27.
    Matzke, G.R., Jameson, J.J., and Halstenson, C.E., 1987, Gentamicin disposition in young and elderly patients with various degrees of renal function, J. Clin. Pharmacol. 27:216–220.PubMedGoogle Scholar
  28. 28.
    Yee, G.C., Lennon, T.P., Gmur, D.J., Kennedy, M.S., and Deeg, H.J., 1986, Age-dependent cyclosporine: Pharmacokinetics in narrow transplant recipients, Clin. Pharmacol. Ther. 40:438–443.PubMedGoogle Scholar
  29. 29.
    Docci, D., 1986, Serum alpha-1-acid glycoprotein (AAG) in chronic renal failure, Nephron 42: 347.PubMedGoogle Scholar
  30. 30.
    Rolan, P.E., Muirhead, M., and Clarkson, A.R., 1986, Increased plasma levels of alpha-1-acid glycoprotein in chronic renal failure are unlikely to be due to decreased renal elimination, Nephron 42:345–346.PubMedGoogle Scholar
  31. 31.
    Echizen, H., Saima, S., Umeda, N., and Ishizaki, T., 1986, Protein binding of disopyramide in liver cirrhosis and in nephrotic syndrome, Clin. Pharmacol. Ther. 40:274–280.PubMedGoogle Scholar
  32. 32.
    Vanholder, R., Van Landschoot, N., De Smet, R., Ringoir, S., and Hakim, R., 1986, Inhibition of drug protein binding (PB) during chronic renal failure, Proc. Am. Soc. Nephrol. 19:64a (Abstract).Google Scholar
  33. 33.
    Gulyassy, P.F., Bottini, A.T., Stanfel, L.A., Jarrard, E.A., and Depner, T.A., 1986, Isolation and chemical identification of inhibitors of plasma ligand binding, Kidney Int. 30:391–398.PubMedGoogle Scholar
  34. 34.
    Mabuchi, H. and Nakahashi, H., 1986, Isolation and characterization of an endogenous drugbinding inhibitor present in uremic serum, Nephron 44:277–281.PubMedGoogle Scholar
  35. 35.
    Mabuchi, H. and Nakahashi, H., 1986, Profiling of endogenous ligand solutes that bind to serum proteins in sera of patients with uremia, Nephron 43:110–116.PubMedGoogle Scholar
  36. 36.
    Svensson, C.K., Woodruff, M.N., Baxter, J.G., and Lalka, D., 1986, Free drug concentration monitoring in clinical practice. Rationale and current status, Clin. Pharmacol. 11:450–469.Google Scholar
  37. 37.
    McKinney, T.D. and Kunnemann, M.E., 1987, Cimetidine transport in rabbit renal cortical brush-border membrane vesicles, Am. J. Physiol. 242:F525–F535.Google Scholar
  38. 38.
    Muirhead, M.R., Somogyi, A.A., Rolan, P.E., and Bochner, F., 1986, Effect of cimetidine on renal and hepatic drug elimination: Studies with triamterene, Clin. Pharmacol. Ther. 40:400–407.PubMedGoogle Scholar
  39. 39.
    Van Crugten, J., Bochner, F., Keal, J., and Somogyi, A., 1985, Selectivity of the cimetidineinduced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs, J. Pharmacol. Exp. Ther. 236:481–487.Google Scholar
  40. 40.
    Somogyi, A. and Muirhead, M., 1987, Pharmacokinetic interactions of cimetidine 1987, Clin. Pharmacol. 12:321–366.Google Scholar
  41. 41.
    Nazario, M., 1986, The hepatic and renal mechanisms of drug interactions with cimetidine, Drug. Intell. Clin. Pharm. 20:342–348.PubMedGoogle Scholar
  42. 42.
    Nierenberg, D.W., 1986, Drug inhibition of penicillin tubular secretion: Concordance between in vitro and clinical findings, J. Pharmacol. Exp. Ther. 240:712–716.Google Scholar
  43. 43.
    Notterman, D.A., Prayer, D.E., Metakis, L., and Reidenberg, M.M., 1986, Stereoselective renal tubular secretion of quinidine and quinine, Clin. Pharmacol. Ther. 40:511–517.PubMedGoogle Scholar
  44. 44.
    Koren, G., 1987, Clinical pharmacokinetic significance of the renal tubular secretion of digoxin. Clin. Pharmacokinet. 13:334–343.PubMedGoogle Scholar
  45. 45.
    Loutzenhiser, R. and Epstein, M., 1987, Calcium antagonists and the kidney, Hosp. Pract. 22: 63–76.Google Scholar
  46. 46.
    Sunderrajan, S., Reams, G., and Bauer, J.H., 1986, Renal effects of diltiazem in primary hypertension, Hypertension 8:238–242.PubMedGoogle Scholar
  47. 47.
    Pelayo, J.C., 1986, Modulation of renal adrenergic effector mechanisms by calcium entry blockers, Am. J. Physiol. 252:F613–F620.Google Scholar
  48. 48.
    Blackshear, J.L., Orlandi, C., Williams, G.H., and Hollenberg, N.K., 1986, The renal response to diltiazem and nifedipine: Comparison with nitroprusside, J. Cardiol. Pharmacol. 8: 37–43.Google Scholar
  49. 49.
    Schmitz, A., 1987, Acute renal effects of oral felodipine in normal man, Eur. J. Clin. Pharmacol. 32:17–22.PubMedGoogle Scholar
  50. 50.
    ter Wee, P.M., Smit, A.J., Rosman, J.B., Sluiter, W.J., and Donker, A.J.M., 1986, Effect of intravenous infusion of low-dose dopamine on renal function in normal individuals and in patients with renal disease, Am. J. Nephrol. 6:42–46.PubMedGoogle Scholar
  51. 51.
    Israel, R., O’Mara, V., Austin, B., Bellucci, A., and Meyer, B.R., 1986, Metoclopramide decreases renal plasma flow, Clin. Pharmacol. Ther. 39:261–264.PubMedGoogle Scholar
  52. 52.
    Strandhoy, J.W., 1985, Role of alpha-2 receptors in the regulation of renal function, J. Cardiovasc. Pharmacol. 7:S28–S33.PubMedGoogle Scholar
  53. 53.
    Goldberg, M. and Gehr, M., 1985, Effects of alpha-2 agonists on renal function in hypertensive humans, J. Cardiovasc. Pharmacol 7:S34–S37.PubMedGoogle Scholar
  54. 54.
    Bennett, W.M., Aronoff, G., Golper, T.A., Morrison, G., Singer, I., and Brater, D.C., 1987, Drug Dosing in Renal Failure: Guidelines for Adults. American College of Physicians, Philadelphia.Google Scholar
  55. 55.
    Reed, W.E., Jr. and Sabatini, S., 1986, The use of drugs in renal failure, Semin. Nephrol 6: 259–295.PubMedGoogle Scholar
  56. 56.
    Bennett, W.M. and Golper, T.A., 1987, Drug therapy in renal disease, in: Scientific American Medicine. Scientific American Publishers, New York, Appendix A1–A29.Google Scholar
  57. 57.
    Brater, D.C., 1987, Drug Use in Clinical Medicine. B.C. Decker, Toronto.Google Scholar
  58. 58.
    Bjornsson, T.D., 1986, Nomogram for drug dosage adjustment in patients with renal failure, Clin. Pharmacol 11:164–170.Google Scholar
  59. 59.
    Burckart, G.J., 1987, Drug kinetics and dosing in organ transplant patients, Trans. Immun. Lett. 4:1–12.Google Scholar
  60. 60.
    Van Scoy, R.E. and Wilson, W.R., 1987, Antimicrobial agents in adult patients with renal insufficiency: Initial dosage and general recommendations, Mayo Clin. Proc. 62:1142–1145.PubMedGoogle Scholar
  61. 61.
    Piveral, K., Miller, S.C., Baird, D.R., and Pleasants, R.A., 1986, Apparently raised serum creatinine levels due to cephalosporins, JAMA 255:323–324.PubMedGoogle Scholar
  62. 62.
    Guay, D.R.P., Meatherall, R.C., and Macaulay, P.A., 1983, Interference of selected secondand third-generation cephalosporins with creatinine determination, Am. J. Hosp. Pharm. 40:435–438.PubMedGoogle Scholar
  63. 63.
    Myre, S.A., McCann, J., First, M.R., and Cluxton, R.B., Jr., 1987, Effect of trimethoprim on serum creatinine in healthy and chronic renal failure volunteers, Ther. Drug Monit. 9:161–165.PubMedGoogle Scholar
  64. 64.
    Rybak, L.P., 1986, Drug ototoxicity, Am. Rev. Pharmacol. Toxicol. 26:79–99.Google Scholar
  65. 65.
    Cutler, R.E., Forland, S.C., St. John Hammond, P.G., and Evans, J.R., 1987, Extracorporeal removal of drugs and poisons by hemodialysis and hemoperfusion, Annu. Rev. Pharmacol. Toxicol. 27:169–191.PubMedGoogle Scholar
  66. 66.
    Choi, L. and Johnson, C.A., 1987, Dialyzability of drugs, Dialysis Transpl. 16:537–540.Google Scholar
  67. 67.
    Derlet, R.W. and Albertson, T.E., 1986, Activated charcoal-past, present and future, West. J. Med. 146:493–496.Google Scholar
  68. 68.
    Bouffet, E., Frappaz, D., Laville, M., Finaz, J., Pinkerton, C.R., Philip, T., and Brunat- Mentigny, M., 1986, Charcoal haemoperfusion and methotrexate toxicity, Lancet 1:1497.PubMedGoogle Scholar
  69. 69.
    Bosch, J.P., 1986, Continuous arteriovenous hemofiltration (CAVH): Operational characteristics and clinical use, AKF Nephrol. Lett. 3:15–26.Google Scholar
  70. 70.
    Golper, T.A., Wedel, S.K., Kaplan, A.A., Saad, A.M., Donta, S., and Paganini, E.P., 1985, Drug removal during continuous arteriovenous hemofiltration: Theory and clinical observation, Int. J. Artif. Organs 8:307–313.PubMedGoogle Scholar
  71. 71.
    Lau, A.H., Kronfol, N.O., and Barakat, M., 1987, Effect of blood and ultrafiltrate flow rates on drug sieving during continuous hemofiltration, Trans. Am. Soc. Artif. Intern. Organs 33:297–299.Google Scholar
  72. 72.
    Matzke, G.R., O’Connell, M.B., Collins, A.J., and Keshaviah, P.R., 1986, Disposition of vancomycin during hemofiltration, Clin. Pharmacol. Ther. 40:425–430.PubMedGoogle Scholar
  73. 73.
    Lau, A.H., Kronfol, N.O., and John, E., 1987, Increased vancomycin elimination with continuous hemofiltration, Trans. Am. Soc. Artif. Intern. Organs 33:772–774.Google Scholar
  74. 74.
    Domoto, D.T., Brown, W.W., and Bruggensmith, P., 1987, Removal of toxic levels of Nacetylprocainamide with continuous arteriovenous hemofiltration or continuous arteriovenous hemodiafiltration, Ann. Intern. Med. 106:550–552.PubMedGoogle Scholar
  75. 75.
    Braden, G.L., Fitzgibbons, J.P., Germain, M.J., and Ledewitz, H.M., 1986, Hemoperfusion for treatment of N-acetylprocainamide intoxication, Ann. Intern. Med. 105:64–65.PubMedGoogle Scholar
  76. 76.
    Loute, G., Adam, A., Heremans, C., and Willems, B., 1986, The influence of haemodialysis and haemofiltration on the clearance of torasemide in renal failure, Eur. J. Clin. Pharmacol. 3 (Suppl)53–55.Google Scholar
  77. 77.
    Lai, K.N., Swaminathan, R., Pun, C.O., and Vallance-Owen, J., 1986, Hemofiltration in digoxin overdose, Arch. Intern. Med. 146:1219–1221.PubMedGoogle Scholar
  78. 78.
    Zarowitz, B.J., Anandan, J.V., Dumler, F., Jayashankar, J., and Levin, N., 1986, Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients, J. Clin. Pharmacol. 26:686–689.PubMedGoogle Scholar
  79. 79.
    Golper, T.A., Saad, A.-M.A., and Morris, C.D., 1986, Gentamicin and phenytoin sieving through hollow-fiber polysulfone hemofilters, Kidney Int. 30:937–943.PubMedGoogle Scholar
  80. 80.
    Kronfol, N., Lau, A., and Barakat, M., 1987, Aminoglycoside binding to polyacrylonitrile hemofilter membranes during continuous hemofiltration, Trans. Am. Soc. Artif. Intern. Organs 33:297–299.Google Scholar
  81. 81.
    British Society of Antimicrobial Chemotherapy, 1987, Working Party Report: Diagnosis and management of peritonitis in continuous ambulatory peritoneal dialysis, Lancet 1:845–850.Google Scholar
  82. 82.
    Janicke, D.M., Morse, G.D., Apicella, M.A., Jusko, W.J., and Walshe, J.J., 1986, Pharmacokinetic modeling of bidirectional transfer during peritoneal dialysis, Clin. Pharmacol. Ther. 40:209–218.PubMedGoogle Scholar
  83. 83.
    Whitby, ML, Edwards, R., Aston, E., and Finch, R.G., 1987, Pharmacokinetics of single dose intravenous vancomycin in CAPD peritonitis, J. Antimicrob. Chemother. 19:351–357.PubMedGoogle Scholar
  84. 84.
    Morse, G.D., Farolino, D.F., Apicella, M.A., and Walshe, J.J., 1987, Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis, Antimicrob. Agents Chemother. 31:173–177.PubMedGoogle Scholar
  85. 85.
    Traina, G.L., Gentile, M.G., Fellin, G., Rosina, R., Cavenaghi, L., Buniva, G., and Bonati, M., 1986, Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis, Eur. J. Clin. Pharmacol. 31:501–504.PubMedGoogle Scholar
  86. 86.
    Harford, A.M., Sica, D.A., Tartaglione, T., Polk, R.E., Dalton, H.P., and Poyner, W., 1986, Vancomycin pharmacokinetics in continuous ambulatory peritoneal dialysis patients with peritonitis, Nephron 43:217–222.PubMedGoogle Scholar
  87. 87.
    Walshe, J.J. and Morse, G.D., 1986, The influence of peritonitis on the pharmacokinetics of intraperitoneal vancomycin, Proc. Am. Soc. Nephrol. 19:99a (Abstract).Google Scholar
  88. 88.
    Shah, G.M., Winer, R.L., and Krasny, H.C., 1986, Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis, Am. J. Kidney Dis. 7:507–510.PubMedGoogle Scholar
  89. 89.
    Boelaert, J., Schurgers, M., Daneels, R., Van Landuyt, H.W., and Weatherley, B.C., 1987, Multiple dose pharmacokinetics of intravenous acyclovir in patients on continuous ambulatory peritoneal dialysis, J. Antimicrob. Chemother. 20:69–76.PubMedGoogle Scholar
  90. 90.
    Rubin, J., Deraps, G.D., Walsh, D., Adair, C., and Bower, J., 1986, Protein losses and tobramycin absorption in peritonitis treated by hourly peritoneal dialysis, Am. J. Kidney Dis. 8: 124–127.PubMedGoogle Scholar
  91. 91.
    Indraprasit, S., Ukaravichien, V., Pummangura, C., and Kaojarern, S., 1986, Gentamicin removal during intermittent peritoneal dialysis, Nephron 44:18–21.PubMedGoogle Scholar
  92. 92.
    Bliss, M., Mayersohn, M., Arnold, T., Logan, J., Michael, U.F., and Jones, W., 1986, Disposition kinetics of cefamandole during continuous ambulatory peritoneal dialysis, Antimicrob. Agents Chemother. 29:649–653.PubMedGoogle Scholar
  93. 93.
    Raehl, C.L., Moorthy, A.V., and Beirne, G.J., 1986, Procainamide pharmacokinetics in patients on continuous ambulatory peritoneal dialysis, Nephron 44:191–194.PubMedGoogle Scholar
  94. 94.
    Sica, D.A., Comstock, T., Harford, A., and Eshelman, F., 1987, Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis, Eur. J. Clin. Pharmacol. 32:587–591.PubMedGoogle Scholar
  95. 95.
    Raehl, C.L., Beirne, G.J., Moorthy, A.V., and Patel, A.K., 1987, Tocainide pharmacokinetics during continuous ambulatory peritoneal dialysis, Am. J. Cardiol. 60:747–750.PubMedGoogle Scholar
  96. 96.
    Heim, K.L., Halstenson, C.E., Comty, C.M., Affrime, M.B., and Matzke, G.R., 1986, Disposition of cefotaxime and desacetyl cefotaxime during continuous ambulatory peritoneal dialysis, Antimicrob. Agents Chemother. 30:15–19.PubMedGoogle Scholar
  97. 97.
    Albin, H., Ragnaud, J.M., Demotes-Mainard, F., Vincon, G., Couzineau, M., and Wone, C., 1986, Pharmacokinetics of intravenous and intraperitoneal ciftriaxone in chronic ambulatory peritoneal dialysis, Eur. J. Clin. Pharmacol. 31:479–483.PubMedGoogle Scholar
  98. 98.
    Albin, H., Ragnaud, J.M., Demotes-Mainard, F., Vincon, G., and Wone, C., 1986, Pharmacokinetics of intravenous and intraperitoneal ciftriaxone in chronic ambulatory peritoneal dialysis, Eur. J. Clin. Pharmacol. 30:299–302.PubMedGoogle Scholar
  99. 99.
    Schwartz, M.T., Kowalsky, S.F., McCormick, E.M., Parker, M.A., and Echols, R.M., 1986, Clindamycin phosphate kinetics in subjects undergoing CAPD, Clin. Nephrol. 26:303–306.PubMedGoogle Scholar
  100. 100.
    Walshe, J.J. and Janicke, D.M., 1986, Crossover pharmacokinetic analysis comparing intravenous and intraperitoneal administration of tobramycin, J. Infect. Dis. 153:796–799.PubMedGoogle Scholar
  101. 101.
    Golper, T.A., Hartstein, A.I., Morthland, V.H., and Christensen, J.M., 1987, Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis, Antimicrob. Agents Chemother. 31:1787–1790.PubMedGoogle Scholar
  102. 102.
    Reams, G.P., Young, M., Sorkin, M., Twardowski, Z., Gloor, H., Moore, H., and Nolph, K.D., 1985-86, Effects of dipyridamole on peritoneal clearances, Uremia Invest. 9:27–33.PubMedGoogle Scholar
  103. 103.
    Maher, J.F., Kirszel, P., Chakrabarti, E., and Bennett, R.R., 1986, Contrasting effects of amphotericin B and the solvent sodium desoxycholate on peritoneal transport, Nephron 43:38–42.PubMedGoogle Scholar
  104. 104.
    Kayser, S.R. and Kurisu, S., 1986, Hydroxocobalamin in nitroprusside-induced cyanide toxicity, Drug IntelL Clin. Pharm. 20:365–366.Google Scholar
  105. 105.
    Antal, E.J., Wright, C.E., Ill, Brown, B.L., Albert, K.S., Aman, L.C., and Levin, N.W., 1986, The influence of hemodialysis on the pharmacokinetics of ibuprofen and its major metabolites, J. Clin. Pharmacol. 26:184–190.PubMedGoogle Scholar
  106. 106.
    Evers, J., Bonn, R., Boertz, A., Cawello, W., Luckow, V., Fey, M., Aboudan, F., and Dickmans, H-A., 1987, Pharmacokinetics of isosorbide-f-nitrate during haemodialysis and peritoneal dialysis, Eur. J. Clin. Pharmacol. 32:503–505.PubMedGoogle Scholar
  107. 107.
    Eisenberg, J.M., Koffer, H., Glick, H.A., Connell, M.L., Loss, L.E., Talbot, G.H., Shusterman, N.H., and Strom, B.L., 1987, What is the cost of nephrotoxicity associated with aminoglycosides? Ann. Intern. Med. 107:900–909.PubMedGoogle Scholar
  108. 108.
    Mathews, A. and Bailie, G.R., 1989, High incidence of nephrotoxicity with aminoglycosides dosed by non-pharmacokinetic methods, Nephron (in press).Google Scholar
  109. 109.
    Rybak, M.J., Frankowski, J.J., Edwards, D.J., and Albrecht, L.M., 1987, Alanine aminopeptidase and β2-microglobulin excretion in patients receiving vancomycin and gentamicin, Antimicrob. Agents Chemother. 31:1461–1464.PubMedGoogle Scholar
  110. 110.
    Cimino, M.A., Rotstein, C., Slaughter, R.L., and Emrich, L.J., 1987, Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy, Am. J. Med. 83:1091–1097.PubMedGoogle Scholar
  111. 111.
    Keller, F., Wagner, K., Borner, K., Kemmerich, B., Lode, H., Offermann, G., and Distler, A., 1986, Aminoglycoside dosage in hemodialysis patients, J. Clin. Pharmacol. 26:690–695.PubMedGoogle Scholar
  112. 112.
    Rodvold, K.A. and Blum, R.A., 1987, Predictive performance of Sawchuk-Zaske and Bayesian dosing methods for tobramycin, J. Clin. Pharmacol. 27:419–427.PubMedGoogle Scholar
  113. 113.
    Nahata, M.C., Hippie, T.F., and Clotz, M., 1986, Interlot variability in gentamicin and tobramycin concentration and its possible significance, Ther. Drug. Monit. 8:256–258.PubMedGoogle Scholar
  114. 114.
    Frazier, D.L. and Riviere, J.E., 1987, Gentamicin dosing strategies for dogs with subclinical renal dysfunction, Antimicrob. Agents Chemother. 31:1929–1934.PubMedGoogle Scholar
  115. 115.
    Winslade, N.E., Adelman, M.H., Evans, E.J., and Schentag, J.J., 1987, Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers, Antimicrob. Agents Chemother. 31:605–609.PubMedGoogle Scholar
  116. 116.
    Fillastre, J.P., Leroy, A., Humbert, G., Moulin, B., Bernadet, P., and Josse, S., 1987, Pharmacokinetics of habekacin in patients with renal insufficiency, Antimicrob. Agents Chemother. 31: 575–577.PubMedGoogle Scholar
  117. 117.
    Edson, R.S. and Terrell, C.L., 1987, The aminoglycosides: Streptomycin, kanamycin, gentamicin, tobramycin, amikacin, netilmicin, and sisomicin, Mayo Clin. Proc. 62:916–920.PubMedGoogle Scholar
  118. 118.
    Wise, R., 1986, In vitro and pharmacokinetic properties of the carbapenems, Antimicrob. Agents Chemother. 30:343–349.PubMedGoogle Scholar
  119. 119.
    Rogers, J.D., Meisinger, A.P., Ferber, F., Calandra, G.B., Demetriades, J.L., and Bland, J.A., 1985, Pharmacokinetics of impipenem and cilastatin in volunteers, Ann. Infect. Dis. 7: S435–S634.Google Scholar
  120. 120.
    Anon., 1986, Imipenem-cilastatin sodium (primaxin), Med. Lett. 28:29–32.Google Scholar
  121. 121.
    Clissold, S.P., Todd, A., and Campoli-Richards, D.M., 1987, Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy, Drugs 33:183–241.PubMedGoogle Scholar
  122. 122.
    Thompson, R.L., 1987, Cephalosporin, carbapenem, and monobactam antibiotics, Mayo Clin. Proc. 62:821–834.PubMedGoogle Scholar
  123. 123.
    Bergan, T., 1987, Pharmacokinetic properties of the cephalosporins, Drugs 34:89–104.PubMedGoogle Scholar
  124. 124.
    Smith, B.R., LeFrock, J.L., Thyrum, P.T., Doret, B.A., Yeh, C., Onesti, G., Schwartz, A., and Zimmerman, J.J., 1986, Cefotetan pharmacokinetics in volunteers with various degrees of renal function, Antimicrob. Agents Chemother. 29:887–893.PubMedGoogle Scholar
  125. 125.
    Browning, M.J., Holt, H.A., White, L.O., Chapman, S.T., Banks, R.A., Reeves, D.S., and Yates, R.A., 1986, Pharmacokinetics of cefotetan in patients with end-stage renal failure on maintenance dialysis, J. Antimicrob. Chemother. 18:103–106.PubMedGoogle Scholar
  126. 126.
    Konishi, K., 1986, Pharmacokinetics of cefmenoxime in patients with impaired renal function and in those undergoing hemodialysis, Antimicrob. Agents Chemother. 30:901–905.PubMedGoogle Scholar
  127. 127.
    Campoli-Richards, D.M. and Todd, P.A., 1987, Cefmenoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use, Drugs 34:188–221.PubMedGoogle Scholar
  128. 128.
    van Dalen, R., Baars, A.M., and Termond, E., 1986, Dosage adjustment for ceftazidime in patients with impaired renal function, Eur. J. Clin. Pharmacol. 30:597–605.PubMedGoogle Scholar
  129. 129.
    Phelps, R.G. and Conte, J.E., Jr., Multiple-dose pharmacokinetics of cefonicid in patients with impaired renal function, Antimicrob. Agents Chemother. 29:913–917.Google Scholar
  130. 130.
    Saltiel, E. and Brogden, R.N., 1986, Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use, Drugs 32:222–259.PubMedGoogle Scholar
  131. 131.
    Campoli-Richards, D.M., Lackner, T.E., and Monk, J.P., 1987, Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy, Drugs 34:411–437.PubMedGoogle Scholar
  132. 132.
    Barrueco, M., Otero, M.J., Garcia, M.J., Lanao, J.M., and Dominguez-Gil, A., 1986, Pleural fluid levels of cefoxitin in patients with renal impairment, Int. J. Clin. Pharm. Ther. Toxicol. 24: 485–489.Google Scholar
  133. 133.
    Guay, D.R.P., Meatherall, R.C., Harding, G.K., and Brown, G.R., 1986, Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency, Antimicrob. Agents Chemother. 30:485–490.PubMedGoogle Scholar
  134. 134.
    Tanrisever, B. and Santella, P.J., 1986, Cefadroxil. A review of its antibacterial, pharmacokinetic and therapeutic properties in comparison with cephalexin and cephradine, Drugs 32:1–16.PubMedGoogle Scholar
  135. 135.
    Wright, D.B., 1986, Cefsulodin, Drug Intell. Clin. Pharm. 20:845–849.PubMedGoogle Scholar
  136. 136.
    Conte, J.E., Jr., 1987, Pharmacokinetics of cefpiramide in volunteers with normal or impaired renal function, Antimicrob. Agents Chemother. 31:1585–1588.PubMedGoogle Scholar
  137. 137.
    Aronoff, G.R., Wolen, R.L., Obermeyer, B.D., and Black, H.R., 1986, Pharmacokinetics and protein binding of cefamandole and its 1-methyl-1 H-tetrazole-5-thiol side chain in subjects with normal and impaired renal function, J. Infect. Dis. 153:1069–1074.PubMedGoogle Scholar
  138. 138.
    Babiak, L.M. and Rybak, M.J., 1986, Hematological effects associated with beta-lactam use, Drug Intell. Clin. Pharm. 20:833–836.PubMedGoogle Scholar
  139. 139.
    Josse, S., Godin, M., and Fillastre, J.P., 1987, Cefazolin-induced encephalopathy in a uraemic patients, Nephron 45:72.PubMedGoogle Scholar
  140. 140.
    Childs, S.J. and Bodey, G.P., 1986, Aztreonam, Pharmacotherapy 6:138–152.PubMedGoogle Scholar
  141. 141.
    Anon., 1987, Aztreonam (Azactam), Med. Lett. 29:45–48.Google Scholar
  142. 142.
    Anon., 1987, Ampicillin/sulbactam (Unasyn), Med. Lett. 29:79–82.Google Scholar
  143. 143.
    Campoli-Richards and Brogden, R.N., 1987, Sulbactam/Ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use, Drugs 33:577–609.PubMedGoogle Scholar
  144. 144.
    Foulds, G., 1986, Pharmacokinetics of sulbactam/Ampicillin in humans: A review, Rev. Infect. Dis. 8:S503–S511.PubMedGoogle Scholar
  145. 145.
    Horber, F.F., Frey, F.J., Descoeudres, C., Murray, A.T., and Reubi, F.C., 1986, Differential effect of impaired renal function on the kinetics of clavulanic acid and amoxicillin, Antimicrob. Agents Chemother. 29:614–619.PubMedGoogle Scholar
  146. 146.
    Dalet, F., Amado, E., Donate, T., and del Rio, G., 1986, Pharmacokinetics of the combination if ticarcillin with clavulanic acid in renal insufficiency, J. Antimicrob. Chemother. 17:57–64.PubMedGoogle Scholar
  147. 147.
    Jungbluth, G.L., Cooper, D.L., Doyle, G.D., Chudzik, G.M., and Jusko, W.J., 1986, Pharmacokinetics of ticarcillin and clavulanic acid (Timentin) in relation to renal function, Antimicrob. Agents Chemother. 30:896–900.PubMedGoogle Scholar
  148. 148.
    Watson, I.D., Boulton-Jones, M., Stewart, M.J., Henderson, I., and Payton, C.D., 1987, Pharmacokinetics of clavulanic acid-potentiated ticarcillin in renal failure, Ther. Drug. Monit. 9: 139–147.PubMedGoogle Scholar
  149. 149.
    Wright, A.J. and Wilkowske, C.J., 1987, The penicillins, Mayo Clin. Proc. 62:806–820.PubMedGoogle Scholar
  150. 150.
    Terp, D.K. and Rybank, M.J., 1987, Ciprofloxacin, Drug Intell. Clin. Pharm. 21:568–74.PubMedGoogle Scholar
  151. 151.
    Marble, D.A. and Bosso, J.A., 1986, Norfloxacin: A quinoline antibiotic, Drug Intell. Clin. Pharm. 20:261–6.PubMedGoogle Scholar
  152. 152.
    Rowen, R.C., Michel, D.J., and Thompson, J.C., 1987, Norfloxacin: Clinical pharmacology and clinical use, Pharmacotherapy 7:92–110.PubMedGoogle Scholar
  153. 153.
    Gasser, T.C., Ebert, S.C., Graversen, P.H., and Madsen, P. O., 1987, Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function, Antimicrob. Agents Chemother. 31: 709–712.PubMedGoogle Scholar
  154. 154.
    Gerritisen, W.R., Peters, A., Henry, F.C., and Brouwers, J., 1987, Cirprofoxacin-induced nephrotoxicity, Nephrol. Dialysis Transpl. 2:382–383.Google Scholar
  155. 155.
    Dudley, M.N., 1987, Pharmacokinetic and pharmacodynamic properties of new quinoline antiinfectives, Hosp. Formul. 22:9–15.Google Scholar
  156. 156.
    Drusano, G.L., Weir, M., Forrest, A., Plaisance, K., Emm, T., and Standiford, H.C., 1987, Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function, Antimicrob. Agents Chemother. 31:860–864.PubMedGoogle Scholar
  157. 157.
    Lode, H., Hoffken, G., Prinzing, C., Glatzel, R., Olschewski, W.P., Sivers, B., Reimnitz, D., Borner, K., and Koeppe, P., 1987, Comparative pharmacokinetics of new quinolones, Drugs 34: 21–25.PubMedGoogle Scholar
  158. 158.
    Wise, R., Lister, D., McNulty, C.A.M., Griggs, D., and Andrews, J.M., 1986, The comparative pharmacokinetics of five quinolones, J. Antimicrob. Chemother. 18:71–81.PubMedGoogle Scholar
  159. 159.
    LeBel, M., Barbeau, G., Bergeron, M.G., Roy, D., and Vallée, F., 1986, Pharmacokinetics of ciprofloxacin in elderly subjects, Pharmacotherapy 6:87–91.PubMedGoogle Scholar
  160. 160.
    Webb, D.B., Roberts, D.E., Williams, J.D., and Asscher, A.W., 1986, Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney funtion, J. Antimicrob. Chemother. 18:83–87.PubMedGoogle Scholar
  161. 161.
    Singlas, E., Taburet, A.M., Landru, I., Albin, H., and Ryckelinck, J. Ph., 1987, Pharmacokinetics of ciprofloxacin tablets in renal failure; Influence of haemodialysis. Eur. J. Clin. Pharmacol. 31:589–593.PubMedGoogle Scholar
  162. 161a.
    Shalit, I., Greenwood, R.B., Marks, M.I., Pederson, J.A., and Frederick, D.L., 1986, Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis, Antimicrob. Agents Chemother. 30(1): 152–156.PubMedGoogle Scholar
  163. 162.
    Anon., 1987, Safety of antimicrobial drugs in pregnancy, Med. Lett. 29:61–63.Google Scholar
  164. 163.
    Boelaert, J., de Jaegere, P.P., Daneels, R., Schurgers, M., Gordts, B., and van Landuyt, H.W., 1987, Case report of renal failure during norfloxacin therapy, Clin. Nephrol. 27:272.Google Scholar
  165. 164.
    Monk, J.P. and Campoli-Richards, D.M., 1987, Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use, Drugs 33:346–391.PubMedGoogle Scholar
  166. 165.
    Fillastre, J.P., Leroy, A., and Humbert, G., 1987, Ofloxacin pharmacokinetics in renal failure, Antimicrob. Agents Chemother. 31:156–160.PubMedGoogle Scholar
  167. 166.
    Bury, R.W., Becker, G.J., Kincaid-Smith, P.S., Moulds, R.W., and Whitworth, J.A., 1987, Elimination of enoxacin in renal disease, Clin. Pharmacol. Ther. 41:434–8.PubMedGoogle Scholar
  168. 167.
    Rybak, M.J. and Boike, S.C., 1986, Monitoring vancomycin therapy, Drug Intell. Clin. Pharm. 20:757–761.PubMedGoogle Scholar
  169. 168.
    Cheung, R. P. F. and DiPiro, J. T., 1986, Vancomycin: An update, Pharmacotherapy 6:153–169.PubMedGoogle Scholar
  170. 169.
    Golper, T., Noonan, H., Anderson, J., Elzinga, L., Brummeh, R., Andersen, J.L., Gilbert, D., and Bennett, W., 1988, Vancomycin pharmacokinetics: renal handling and nonrenal clearances in normal subjects, Clin. Pharmacol. Ther. 43:565–570.PubMedGoogle Scholar
  171. 170.
    Healy, D.P., Polk, R.E., Garson, M.L., Rock, D.T., and Comstock, T.J., 1987, Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers, Antimicrob. Agents Chemother. 31:393–397.PubMedGoogle Scholar
  172. 171.
    Southorn, P.A., Plevak, D.J., Wright, A.J., and Wilson, W.R., 1986, Adverse effects of vancomycin administered in the perioperative period, Mayo Clin. Proc. 61:721–724.PubMedGoogle Scholar
  173. 172.
    Hermans, P.E. and Wilhelm, M.P., 1987, Vancomycin, Mayo Clin. Proc. 62:901–905.PubMedGoogle Scholar
  174. 173.
    Arroyo, J.C., Rosansky, S.J., and Rosenzweig, P.N., 1986, Correspondence, Am. J. Kidney Dis. 7:511.PubMedGoogle Scholar
  175. 174.
    Packer, J., Olshan, A.R., and Schwartz, A.B., 1987, Prolonged allergic reaction to vancomycin in end-stage renal disease, Dialysis Transpl. 16:86–88.Google Scholar
  176. 175.
    Matzke, G.R., Halstenson, C.E., Olson, P.L., Collins, A.J., and Abraham, P.A., 1987, Systemic absorption of oral vancomycin in patients with renal insufficiency and antibiotic-associated colitis, Am. J. Kidney Dis. 9:422–425.PubMedGoogle Scholar
  177. 176.
    Bonati, ML, Traina, Villa, G., Salvadeo, A., Gentile, M.G., Fellin, G., Rosina, R., Cavenaghi, L., and Buniva, G., 1987, Teicoplanin pharmacokinetics in patients with chronic renal failure, Clin. Pharmacol. 12:292–301.Google Scholar
  178. 177.
    Falcoz, C., Ferry, N., Pozet, N., Cuisinaud, G., Zech, P.Y., and Sassard, J., 1987, Pharmacokinetics of teicoplanin in renal failure, Antimicrob. Agents Chemother. 31:1255–1262.PubMedGoogle Scholar
  179. 178.
    Domart, Y., Pierre, C., Clair, B., Garaud, J.J., Regnier, B., and Gibert, C., 1987, Pharmacokinetics of teicoplanin in critically ill patients with various degrees of renal impairment, Antimicrob. Agents Chemother. 31:1600–1604.PubMedGoogle Scholar
  180. 179.
    Wilson, W.R. and Cockerill, F.R., III., 1987, Tetracyclines, chloramphenicol, erythromycin, and clindamycin, Mayo Clin. Proc. 62:906–915.PubMedGoogle Scholar
  181. 180.
    Disse, B., Gundert-Remy, U., Weber, E., Andrassy, K., Sietzen, W., and Lang, A., 1986, Pharmacokinetics of erythromycin in patients with different degrees of renal impairment, Int. J. Clin. Pharm. Ther. Toxicol. 24:460–464.Google Scholar
  182. 181.
    Kanfer, A., Stamatakis, G., Torlotin, J.C., Fredj, G., Kenouch, S., and Méry, J. Ph., 1987, Changes in erythromycin pharmacokinetics induced by renal failure, Clin. Nephrol. 27:147–150.PubMedGoogle Scholar
  183. 182.
    Goa, K.L. and Campoli-Richards, D.M., 1987, Pentamidine isethionate. A review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in pneumocystic carinii pneumonia, Drugs 33:242–258.PubMedGoogle Scholar
  184. 183.
    Conte, J.E., Upton, R.A., Phelps, R.T., Wofsy, C.B., Zurlinden, E., and Lin, E.T., 1986, Use of a specific and sensitive assay to determine pentamidine pharmacokinetics in patients with AIDS, J. Infect. Dis. 154:923–929.PubMedGoogle Scholar
  185. 184.
    Bergan, T., Ortengren, B., and Westerlund, D., 1986, Clinical pharmacokinetics of co-trimazine, Clin. Pharm. 11:372–386.Google Scholar
  186. 185.
    Nissenson, A.R., Wilson, C., and Holazo, A., 1987, Pharmacokinetics of intravenous trimethoprim- sulfamethoxazole during hemodialysis, Am. J. Nephrol. 7:270–274.PubMedGoogle Scholar
  187. 186.
    Wood, M.J. and Geddes, A.M., 1987, Antiviral therapy, Lancet 2:1189–1192.PubMedGoogle Scholar
  188. 187.
    Hermans, P.E. and Cockerill, F.R., 1987, Antiviral agents, Mayo Clin. Proc. 62:1108–1115.PubMedGoogle Scholar
  189. 188.
    Jones, P.G. and Beier-Hanratty, S.A., 1986, Acyclovir: Neurologic and renal toxicity, Ann. Intern. Med. 104:892.PubMedGoogle Scholar
  190. 189.
    Spiegal, D.M. and Lau, K., 1986, Acute renal failure and coma secondary to acyclovir therapy, JAMA 255:1882–1883.PubMedGoogle Scholar
  191. 190.
    Dorsky, D.I. and Crumpacker, C.S., 1987, Drugs five years later: Acyclovir, Ann. Intern. Med. 107:859–874.PubMedGoogle Scholar
  192. 191.
    Laskin, O.L., Cederberg, D.M., Mills, J., Eron, L.J., Mildvan, D., and Spector, S.A., 1987, Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus, Am. J. Med. 83:201–207.PubMedGoogle Scholar
  193. 192.
    Fletcher, C., Sawchuk, R., Chinnock, B., de Miranda, P., and Balfour, H.H., Jr., 1986, Human pharmacokinetics of the antiviral drug DHPG, Clin. Pharmacol. Ther. 40:281–286.PubMedGoogle Scholar
  194. 193.
    Varughese, A., Brater, D.C., Benet, L.Z., and Lee, C-S.C., 1986, Ethambutol kinetics in patients with impaired renal function, Am. Rev. Respir. Dis. 134:34–38.PubMedGoogle Scholar
  195. 194.
    Van Scoy, R.E. and Wilkowske, C.J., 1987, antituberculous agents, Mayo Clin. Proc. 62:1129–1136.PubMedGoogle Scholar
  196. 195.
    Anon., 1986, Drugs for treatment of systemic fungal infections, Med. Lett. 28:41–44.Google Scholar
  197. 196.
    Terrell, C.L. and Hermans, P.E., 1987, Antifungal agents used for deep-seated mycotic infections, Mayo Clin. Proc. 62:1116–1128.PubMedGoogle Scholar
  198. 197.
    Katz, M., 1986, Anthelmintics. Current concepts in the treatment of helminthic infections, Drugs 32:358–371.PubMedGoogle Scholar
  199. 198.
    Marriner, S.E., Morris, D.L., Dickson, B., and Bogan, J.A., 1986, Pharmacokinetics of albendazole in man, Eur. J. Clin. Pharmacol. 30:705–708.PubMedGoogle Scholar
  200. 199.
    Zuidema, J., Hilbers-Modderman, E.S.M., and Merkus, F.W.H.M., 1986, Clinical pharmacokinetics of dapsone, Clin. Pharm. 11:299–315.Google Scholar
  201. 200.
    Anon., 1986, Drugs for cardiac arrhythmias, Med. Lett. 28:111–116.Google Scholar
  202. 201.
    Kreeger, R.W. and Hammill, S.C., 1987, New antiarrhythmic drugs: Tocainide, mexiletine, flecainide, encainide, and amiodarone, Mayo Clin. Proc. 62:1033–1050.PubMedGoogle Scholar
  203. 202.
    Oates, J.A., Wood, A.J.J., and Campbell, R.W.F., 1987, Drug therapy. Mexiletine, N. Engl. J. Med. 316:29–34.Google Scholar
  204. 203.
    Anon., 1986, Mexiletine for arrhythmias, Med. Lett. 28:65–68.Google Scholar
  205. 204.
    Roden, D.M. and Woosley, R.L., 1986, Drug therapy. Tocainide, N. Engl. J. Med. 315:41–45.PubMedGoogle Scholar
  206. 205.
    Roden, D.M. and Woosley, R.L., 1986, Drug therapy. Flecainide, N. Engl. J. Med. 315:36–40.PubMedGoogle Scholar
  207. 206.
    Braun, J., Kollert, J.R., and Becker, J.U., 1987, Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal renal function, Eur. J. Clin. Pharmacol. 31:711–714.PubMedGoogle Scholar
  208. 207.
    Salerno, D.M., Granrud, G., Sharkey, P., Krejci, J., Larson, T., Erlien, D., Berry, D., and Hodges, M., 1986, Pharmacodynamics and side effects of flecainide acetate, Clin. Pharmacol. Ther. 40:101–107.PubMedGoogle Scholar
  209. 208.
    Bergstrand, R.H., Wang, T., Roden, D.M., Stone, W.J., Wolfenden, H.T., Woosley, R.L., Wilkinson, G.R., and Wood, A.J.J., 1986, Encainide disposition in patients with renal failure, Clin. Pharmacol. Ther. 40:64–70.PubMedGoogle Scholar
  210. 209.
    Tordjman, T. and Estes, N.A.M., 1987, Encainide: Its electrophysiologic and antiarrhythmic effects, pharmacokinetics, and safety, Pharmacotherapy 7:149–163.PubMedGoogle Scholar
  211. 210.
    Brogden, R.N. and Todd, P.A., 1987, Encainide. A review of its pharmacological properties and therapeutic efficacy, Drugs 34:519–538.PubMedGoogle Scholar
  212. 211.
    Brogden, R.N. and Todd, P.A., 1987, Disopyramide. A reappraisal of its pharmacodynamics and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias, Drugs 34:151–187.PubMedGoogle Scholar
  213. 212.
    Siddoway, L.A. and Woosley, R.L., 1986, Clinical pharmacokinetics of disopyramide, Clin. Pharmacol 11:214–222.Google Scholar
  214. 213.
    Anon., 1986, Amiodarone, Med. Lett. 28:49–52.Google Scholar
  215. 214.
    Oates, J.A., Wood, A.J.J., and Mason, J.W., 1987, Drug therapy. Amiodarone, N. Engl J. Med. 316:455–466.Google Scholar
  216. 215.
    Garfinkel, D., Mamelok, R.D., and Blaschke, T.F., 1987, Altered therapeutic range for quinidine after myocardial infarction and cardiac surgery, Ann. Intern. Med. 107:48–50.PubMedGoogle Scholar
  217. 216.
    Harron, D.W.G. and Brogden, R.N., 1987, Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias, Drugs 34:617–647.PubMedGoogle Scholar
  218. 217.
    Rosansky, S.J. and Brady, M.E., 1986, Procainamide toxicity in a patient with acute renal failure, Am. J. Kidney Dis. 7:502–506.PubMedGoogle Scholar
  219. 218.
    Weisbart, R.H., Yee, W.S., Colburn, K.K., Whang, S.H., Heng, M.K., and Boucek, R.J., 1986, Antiguanosine antibodies: A new marker for procainamide-induced systemic lupus erythematosus, Ann. Intern. Med. 104:310–313.PubMedGoogle Scholar
  220. 219.
    Rocci, M.L., Jr. and Wilson, H., 1987, The pharmacokinetics and pharmacodynamics of newer inotropic agents, Clin. Pharm. 13:91–109.Google Scholar
  221. 220.
    Weber, K.T., Gill, S.K., Janicki, J.S., Maskin, C.S., and Jain, M.C., 1987, Newer positive inotropic agents in the treatment of chronic cardiac failure, Drugs 33:503–519.PubMedGoogle Scholar
  222. 221.
    Oates, J.A., Wood, A.J.J., and Fitzgerald, G.A., 1987, Drug therapy. Dipyridamole, N. Engl J. Med. 316:1247–1256.Google Scholar
  223. 222.
    Kampmann, J.P., 1987, Pharmacokinetics of various preparations of organic nitrates, Drugs 33 (Suppl 4)5–8.PubMedGoogle Scholar
  224. 223.
    Bogaert, M.G., 1987, Clinical pharmacokinetics of glyceryl trinitrate following the use of systemic and topical preparations, Clin. Pharmacol 12:1–11.Google Scholar
  225. 224.
    Evers, J., Krakamp, B., Klimkait, W., Dickmans, H.A., Maddock, J., Luckow, V., Caweilo, W., and Weib, M., 1986, Pharmacokinetics of isosorbide-5-nitrate in renal failure, Eur. J. Clin. Pharmacol 30:349–350.PubMedGoogle Scholar
  226. 225.
    Evers, J., Bonn, R., Caweilo, W., Luckow, V., Aboudan, F., and Dickmans, H.A., 1987, Pharmacokinetics of isosorbide-5-nitrate during haemodialysis and peritoneal dialysis, Eur. J. Clin. Pharmacol 32:503–505.PubMedGoogle Scholar
  227. 226.
    Anon., 1987, Drugs that cause sexual dysfunction, Med. Lett. 29:65–70.Google Scholar
  228. 227.
    Anon., 1987, Drugs for hypertension, Med. Lett. 29:1–6.Google Scholar
  229. 228.
    Morrison, G., Spar, B., Walker, B.R., and Goldfarb, S., 1986, The acute and chronic effects of indoramin on renal function, hemodynamics, and transport, J. Cardiol Pharm. 8(Suppl 2)S25–S29.Google Scholar
  230. 229.
    Titmarsh, S. and Monk, J.P., 1987, Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension, Drugs 33:461–477.PubMedGoogle Scholar
  231. 230.
    Sonders, R.C., 1986, Pharmacokinetics of Terazosin, Am. J. Med. 80(Suppl 5B)20–24.PubMedGoogle Scholar
  232. 231.
    Jungers, P., Ganeval, D., Pertuiset, N., and Chauveau, P., 1986, Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of Terazosin, Am. J. Med. 80(Suppl 5B)94–99.PubMedGoogle Scholar
  233. 232.
    Carlson, R.V., Bailey, R.R., Begg, E.J., Cowlishaw, M.G., and Sharman, J.R., 1986, Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure, Clin. Pharmacol Ther. 40:561–566.PubMedGoogle Scholar
  234. 233.
    Lameire, N. and Gordts, J., 1986, A pharmacokinetic study of prazosin in patients with varying degrees of chronic renal failure, Eur. J. Clin. Pharmacol 31:333–337.PubMedGoogle Scholar
  235. 234.
    Halstenson, C.E., Opsahl, J.A., Pence, T.V., Luke, D.R., Sirgo, M.A., Plachetka, J.R., Abraham, P.A., and Matzke, G.R., 1986, The disposition and dynamics of labetalol in patients on dialysis, Clin. Pharmacol Ther. 40:462–468.PubMedGoogle Scholar
  236. 235.
    Lowenthal, D.T., Saris, S.D., Porter, R.S., Bies, C., and Falkner, B., 1987, Pharmacokinetics and pharmacodynamics of transdermal clonidine in renal insufficiency, Am. Soc. Hypertension 2: 57a (Abstract).Google Scholar
  237. 236.
    Josselson, J. and Sadler, J.H., 1986, Nephrotic-range proteinuria and hyperglycemia associated with clonidine therapy, Am. J. Med. 80:545–546.PubMedGoogle Scholar
  238. 237.
    Sorkin, E.M. and Heel, R.C., 1986, Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension, Drugs 31:301–336.PubMedGoogle Scholar
  239. 238.
    Gehr, M., MacCarthy, E.P., and Goldberg, M., 1986, Guanabenz: A centrally acting, natriuretic antihypertensive drug, Kidney Int. 29:1203–1208.PubMedGoogle Scholar
  240. 239.
    Kiechel, J.R., 1986, Pharmacokinetics of guanfacine in patients with impaired renal function and in some elderly patients, Am. J. Cardiol 57:18E–21E.PubMedGoogle Scholar
  241. 240.
    Benfield, P. and Sorkin, E.M., 1987, Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, Drugs 33:392–412.PubMedGoogle Scholar
  242. 241.
    Covinsky, J.O., 1987, Esmolol: A novel cardioselective, titratable, intravenous beta-blocker with ultrashort half-life, Drug Intell Clin. Pharm. 21:316–321.PubMedGoogle Scholar
  243. 242.
    Reynolds, R.D., Gorczynski, R.J., andQuon, C.Y., 1986, Pharmacology and pharmacokinetics of Esmolol, J. Clin. Pharmacol 26(Suppl A)A3–A14.PubMedGoogle Scholar
  244. 243.
    Anon., 1987, Esmolol—A short-acting IV beta-blocker, Med. Lett. 29:57–60.Google Scholar
  245. 244.
    Zech, P., Pozet, N., Labeeuw, M., Laville, M., Hadj-Aissa, A., Arkouche, W., and Poncet, J.F., 1986, Acute renal effects of beta-blockers, Am. J. Nephrol 6(Suppl 2) 15–19.PubMedGoogle Scholar
  246. 245.
    Paillard, F., Lantz, B., Leviel, F., and Ardaillou, R., 1986, Renal hemodynamic effects of Tertatolol in essential hypertension, Am. J. Nephrol 6(Suppl 2)40–44.PubMedGoogle Scholar
  247. 246.
    Bauer, J.H., Reams, G.P., and Lau, A., 1987, A comparison of Betaxolol and Nadolol on renal function in essential hypertension, Am. J. Kidney Dis. 10:109–112.PubMedGoogle Scholar
  248. 247.
    Drayer, D.E., 1987, Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers, Pharmacotherapy 7:87–91.PubMedGoogle Scholar
  249. 248.
    Riddell, J.G., Harron, D.W.G., and Shanks, R.G., 1987, Clinical pharmacokinetics of β-adrenoceptor antagonists. An update, Clin. Pharmacol. 12:305–320.Google Scholar
  250. 249.
    Bernard, N., Cuisinaurd, G., Pozet, N., Zech, P.Y., and Sassard, J., 1985, Pharmacokinetics of penbutolol and its metabolites in renal insufficiency, Eur. J. Clin. Pharmacol. 29:215–219.PubMedGoogle Scholar
  251. 250.
    Solimon, M., Massry, S.G., and Campese, V.M., 1986, Renal hemodynamics and pharmacokinetics of bevantolol in patients with impaired renal function, Am. J. Cardiol. 58:21E–24E.PubMedGoogle Scholar
  252. 251.
    Van Der Meulen, J., Reijn, E., Heidendal, G.A.K., Donker, O.E., and Donker, A.J.M., 1986, Comparison of the effects of penbutolol and propranolol on glomerular filtration rate in hypertensive patients with impaired renal function, Br. J. Clin. Pharmacol. 22:469–474.PubMedGoogle Scholar
  253. 252.
    Williams, E.M.V., 1987, Bevantolol: A beta-1 adrenoceptor antagonist with unique additional actions, J. Clin. Pharmacol. 27:450–460.Google Scholar
  254. 253.
    Singh, B.N., Deedwania, P., Nademanee, K., Ward, A., and Sorkin, E.M., 1987, Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use, Drugs 34: 311–349.PubMedGoogle Scholar
  255. 254.
    Riddell, J.G., Shanks, R.G., and Brogden, R.N., 1987, Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris, Drugs 34:438–458.PubMedGoogle Scholar
  256. 255.
    Anon., 1986, Enalapril for hypertension, Med. Lett. 28(714)53–56.Google Scholar
  257. 256.
    Bauer, J.H. and Reams, G.P., 1986, Renal effects of angiotensin converting enzyme inhibitors in hypertension, Am. J. Med. 83(Suppl 4C) 19–27.Google Scholar
  258. 257.
    Nelson, E.B., Pool, J.L., and Taylor, A.A., 1986, Pharmacology of angiotensin converting enzyme inhibitors, Am. J. Med. 81 (Suppl 4C)13–18.PubMedGoogle Scholar
  259. 258.
    Packer, M., Lee, W.H., Yushak, M., and Medina, N., 1986, Comparison of captopril and enalapril in patients with severe chronic heart failure, N. Engl. J. Med. 315:847–53.PubMedGoogle Scholar
  260. 259.
    Hockings, N., Ajayi, A. A, and Reid, J.L., 1986, Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat, Br. J. Clin. Pharmacol. 21:341–348.PubMedGoogle Scholar
  261. 260.
    Fruncillo, R.J., Rocci, J.L., Vlasses, P.H., Mojaverian, P., Shepley, K., Clementi, R.A., Oren, A., Smith, R.D., Till, A.E., Riley, L.J. Jr., Krishna, G., Narins, R.G., and Ferguson, R.K., 1987, Disposition of enalapril and enalaprilat in renal insufficiency, Kidney Int. 31:S117–S122.Google Scholar
  262. 261.
    Creasey, W.A., Funke, P.T., McKinstry, D.N., and Sugerman, A.A., 1986, Pharmacokinetics of captopril in elderly healthy male volunteers, J. Clin. Pharmacol. 26:264–268.PubMedGoogle Scholar
  263. 262.
    Drummer, O.H., Workman, B.S., Miach, P.J., Jarrott, B., and Louis, W.J., 1987, The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: Comparison with patients with normal renal function, Eur. J. Clin. Pharmacol. 32: 267–271.PubMedGoogle Scholar
  264. 263.
    Cleary, J.D. and Taylor, J.W., 1986, Enalapril: A new angiotensin converting enzyme inhibitor, Drug Intell. Clin. Pharmacol. 20:177186.Google Scholar
  265. 264.
    Borek, M., Charlap, S., and Frishman, W., 1987, Enalapril: A long-acting angiotensin-converting enzyme inhibitor, Pharmacotherapy 7:133–148.PubMedGoogle Scholar
  266. 265.
    Madeddu, P., Ena, P., Dessi-Fulgheri, P., Glorioso, N., Cerimele, D., and Rappelli, A., 1986, Captopril-induced proteinuria in hypertensive psoriatic patients, Nephron 44:358–360.PubMedGoogle Scholar
  267. 266.
    Donker, Ab. and J.M., 1987, Nephrotoxicity of angiotensin converting enzyme inhibition, Kidney Int. 31:S132–S137.Google Scholar
  268. 267.
    Hogg, K.J. and Hillis, W.S., 1986, Captopril/metolazone induced renal failure, Lancet 1:501–502.PubMedGoogle Scholar
  269. 268.
    Turney, J.H., 1986, Irreversible renal transplant failure after angiotensin converting enzyme inhibition, Br. Med. J. 292:1672.Google Scholar
  270. 269.
    Brown, A.R. and Williams, P.F., 1986, Irreversible renal transplant failure after enalapril therapy, Br. Med. J. 292:732.Google Scholar
  271. 270.
    Hricik, D.E., 1987, Antihypertensive and renal effects of enalapril in post-transplant hypertension, Clin. Nephrol. 27:250–259.PubMedGoogle Scholar
  272. 271.
    Morice, A.H., Brown, M.J., Lowry, R., and Higenbottam, T., 1987, Angiotensin-converting enzyme and the cough reflex, Lancet 2:1116–1118.PubMedGoogle Scholar
  273. 272.
    Inman, W.H.W., 1986, Enalapril-induced cough, Lancet 1:1218.Google Scholar
  274. 273.
    McNally, E.M., 1987, Cough due to captopril, West. J. Med. 146:226–228.PubMedGoogle Scholar
  275. 274.
    Webb, D., Benjamin, N., Collier, J., and Robinson, B., 1986, Enalapril-induced cough, Lancet 2: 1094.Google Scholar
  276. 275.
    Cleland, J.G.F., Dargie, H.J., Pettigrew, A., Gillen, G., and Robertson, J.I.S., 1986, The effects of captopril on serum digoxin an urinary urea and digoxin clearances in patients with congestive heart failure, Am. Heart J. 112:130–135.PubMedGoogle Scholar
  277. 276.
    Debusmann, E.R., Pujadas, J.O., Lahn, W., Irmisch, R., Jané, F., Kuan, T. S, Mora, J., Walter, U., Eckert, H.G., Hajdú, P., and Metzer, H., 1987, Influence of renal function on the pharmacokinetics of ramipril (HOE 498), Am. J. Cardiol. 59:70D–78D.PubMedGoogle Scholar
  278. 277.
    Aurell, M., Delin, K., Herlitz, H., Ljungman, S., Witte, P.U., and Irmisch, R., 1987, Pharmacokinetics and pharmacodynamics of ramipril in renal failure, Am. J. Cardiol. 59:65D–69D.PubMedGoogle Scholar
  279. 278.
    van Schaik, B.A.M., Geyskes, G.G., and Boer, P., 1987, Lisinopril in hypertensive patients with and without renal failure, Eur. J. Clin. Pharmacol. 32:11–16.PubMedGoogle Scholar
  280. 279.
    Rakhit, A., Hurley, M.E., Tipnis, V., Coleman, J., Rommel, A., and Brunner, H.R., 1986, Pharmacokinetics and pharmacodynamics of pentopril, a new angiotensin-converting-enzyme inhibitor in humans, J. Clin. Pharmacol. 26:156–164.PubMedGoogle Scholar
  281. 280.
    Onoyama, K., Kumagai, H., Inenaga, T., Nanishi, F., Okuda, S., Oh, Y., Omae, T., Hayashi, K., and Fujishima, M., 1986, Pharmacokinetic properties of a new angiotensin I-converting enzyme inhibitor in patients with chronic renal failure, Curr. Ther. Res. 39:671–680.Google Scholar
  282. 281.
    Echizen, H. and Eichelbaum, M., 1986, Clinical pharmacokinetics of verapamil, nifedipine and diltiazem, Clin. Pharmacol. 11:425–449.Google Scholar
  283. 282.
    Anderson, P. 1986, Pharmacokinetics of calcium channel blocking agents, Acta Pharmacol. Toxicol. 58:43–57.Google Scholar
  284. 283.
    Boden, W.E., More, G., Sharma, S., Bough, E.W., Korr, K.S., Young, P.M., and Shulman, R.S., 1986, No increase in serum digoxin concentration with high-dose diltiazem, Am. J. Med. 81:425–428.PubMedGoogle Scholar
  285. 284.
    Carrum, G., Egan, J.M., and Abernethy, D.R., 1986, Diltiazem treatment impairs hepatic drug oxidation: Studies of antipyrine, Clin. Pharmacol. Ther. 40:140–143.PubMedGoogle Scholar
  286. 285.
    Edwards, D.J., Lavoie, R., Beckman, H., Blevins, R., and Rubenfire, M., 1987, The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine, Clin. Pharmacol. Ther. 41:68–73.PubMedGoogle Scholar
  287. 286.
    Abernethy, D.R., Schwartz, J.B., Todd, E.L., Luchi, R., and Snow, E., 1986, Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients, Ann. Intern. Med. 105:329–336.PubMedGoogle Scholar
  288. 287.
    Städler, P., Leonardi, L. Riesen, W., Ziegler, W., Marone, C., and Beretta-Piccoli, C., 1987, Cardiovascular effects of verapamil in essential hypertension, Clin. Pharmacol. Ther. 42:485– 492.PubMedGoogle Scholar
  289. 288.
    Kleinbloesem, C.H., Van Brummelen, P., Woittiez, A.J., Faber, H., and Breimer, D.D., 1986, Influence of haemodialysis on the pharmacokinetics and haemodynamic effects of nifedipine during continuous intravenous infusion, Clin. Pharmacol. 11:316–322.Google Scholar
  290. 289.
    Tishler, M. and Armon, S., 1986, Nifedipine-induced hypokalemia, Drug Intell. Clin. Pharm. 20: 370–371.PubMedGoogle Scholar
  291. 290.
    Bonadonna, A., Bisetto, F., Munaretto, G., Beccari, A., and Stanic, L., 1987, Agranulocytosis during nifedipine treatment in a hemodialysis patient, Nephron 47:306–307.PubMedGoogle Scholar
  292. 291.
    Van Harten, J., Burggraaf, K., Danhof, M., Van Brummelen, P., and Breimer, D.D., 1987, Negligible sublingual absorption of nifedipine, Lancet 1:1363–1364.Google Scholar
  293. 292.
    Sorkin, E.M. and Clissold, S.P., 1987, Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders, Drugs 33:296–345.PubMedGoogle Scholar
  294. 293.
    Dow, R.J. and Graham, D.J.M., 1986, A review of the human metabolism and pharmacokinetics of nicardipine hydrochloride, Br. J. Clin. Pharmacol. 22:195S–202S.Google Scholar
  295. 294.
    Baba, T., Ishizaki, T., Murabayashi, S., Aoyagi, K., Tamasawa, N., and Takebe, K., 1987, Multiple oral doses of nicardipine, a calcium entry blocker: Effects on renal function, plasma renin activity, and aldosterone concentration in mild-to-moderate essential hypertension, Clin. Pharmacol. Ther. 42:232–239.PubMedGoogle Scholar
  296. 295.
    Goa, K.L. and Sorkin, E.M., 1987, Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension, Drugs 33: 123–155.PubMedGoogle Scholar
  297. 296.
    Zeller, F.P. and Spinier, S.A., 1987, Bepridil: A new long-acting calcium channel blocking agent, Drug Intell. Clin. Pharm. 21:487–491.PubMedGoogle Scholar
  298. 297.
    Hirth, C., Federmann, A., and Kazda, S., 1987, The protective effect of the calcium antagonist nisoldipine in glycerol-induced renal failure, in: Diuretics II Chemistry, Pharmacology and Clinical Applications, (J. Ruschett and A. Greenberg, eds.), Elsevier, Amsterdam, pp. 490–493.Google Scholar
  299. 298.
    Hertle, L. and Garthoff, B., 1985, Calcium channel blocker nisoldipine limits ischemic damage in rat kidney, J. Urol. 134:1251–1254.PubMedGoogle Scholar
  300. 299.
    Freedman, D.D. and Waters, D.D., 1987, “Second generation” dihydropyridine calcium antagonists, Drugs 34:578–598.PubMedGoogle Scholar
  301. 300.
    Imbs, J.L., Schmidt, M., and Giesen-Crouse, E., 1987, Pharmacology of loop diuretics: State of the art, Adv. Nephrol. 16:137–158.Google Scholar
  302. 301.
    Beermann, B. and Grind, M., 1987, Clinical pharmacokinetics of some newer diuretics, Clin. Pharmacol. 13:254–266.Google Scholar
  303. 302.
    Feig, P.U., 1986, Cellular mechanism of action of loop diuretics: Implications for drug effectiveness and adverse effects, Am. J. Cardiol. 57:14A–19A.PubMedGoogle Scholar
  304. 303.
    Brater, D.C., Anderson, S.A., and Brown-Cartwright, D., 1986, Response to furosemide in chronic renal insufficiency: Rationale for limited doses, Clin. Pharmacol. Ther. 40:134–139.PubMedGoogle Scholar
  305. 304.
    Sherman, L.G., Liang, C.S., Baumgardner, S., Charuzi, Y., Chardo, F., and Kim, C.S., 1986, Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure, Clin. Pharmacol. Ther. 40:587–594.PubMedGoogle Scholar
  306. 305.
    Walter, U., Rockel, A., Heidland, A., and Heptner, W., 1985, Pharmacokinetics of the loop diuretic piretanide in renal failure, Eur. J. Clin. Pharmacol. 29:337–343.PubMedGoogle Scholar
  307. 306.
    Brater, D.C., Leinfelder, J., and Anderson, S.A., 1987, Clinical pharmacology of torasemide, a new loop diuretic, Clin. Pharmacol. Ther. 42:187–192.PubMedGoogle Scholar
  308. 307.
    Lau, H.S.H., Hyneck, M.L., Berardi, R.R., Swartz, R.D., and Smith, D.E., 1986, Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure, Clin. Pharmacol. Ther. 39:635–645.PubMedGoogle Scholar
  309. 308.
    Voelker, J.R., Cartwright-Brown, D., Anderson, S., Leinfelder, J., Sica, D.A., Kokko, J.P., and Brater, D.C., 1987, Comparison of loop diuretics in patients with chronic renal insufficiency, Kidney Int. 32:572–578.PubMedGoogle Scholar
  310. 309.
    Scoble, J.E., Varghese, Z., Sweny, P., and Moorhead, J., 1986, Renal physiology revisited: Amiloride, Lancet 2:326–328.PubMedGoogle Scholar
  311. 310.
    Fairley, K.F., Woo, K.T., Birch, D.F., Leaker, B.R., and Ratnaike, S., 1986, Triamtereneinduced crystalluria and cylinduria: Clinical and experimental studies, Clin. Nephrol. 26:169–173.PubMedGoogle Scholar
  312. 311.
    Farge, D., Turner, M.W., Roy, R., and Jothy, S., 1986, Dyazide-induced reversible acute renal failure associated with intracellular crystal deposition, Am. J. Kidney Dis. 8:445–449.PubMedGoogle Scholar
  313. 312.
    Jivraj, K.T., Noseworthy, T.W., Friesen, E.G., Shustack, A.S., Konopad, E.M., and Johnston, R.G., 1987, Spironolactone-induced agranulocytosis, Drug Intell. Clin. Pharm. 21: 974–975.PubMedGoogle Scholar
  314. 313.
    Osborne, R.J., Joel, S.P., and Slevin, M.L., 1986, Morphine intoxication in renal failure: The role of morphine-6-glucuronide, Br. Med. J. 292:1548–1549.Google Scholar
  315. 314.
    Chauvin, M., Sandouk, P., Scherrmann, J.M., Farinotti, R., Strumza, P., and Duvaldestin, P., 1987, Morphine pharmacokinetics in renal failure, Anesthesiology 3:327–331.Google Scholar
  316. 315.
    Säwe, J. and Odar-Cederlof, I., 1987, Kinetics of morphine in patients with renal failure, Eur. J. Clin. Pharmacol. 32:377–382.PubMedGoogle Scholar
  317. 316.
    Park, G.R., Shelly, M.P., Manara, A.R., and Quinn, K., 1987, Sedation in intensive care: Morphine and renal failure, Int. Care Med. 13:365–366.Google Scholar
  318. 317.
    Woolner, D.F., Winter, D., Frendin, T.J., Begg, E.J., Lynn, K.L., and Wright, G.J., 1986, Renal failure does not impair the metabolism of morphine, Br. J. Clin. Pharmacol. 22:55–59.PubMedGoogle Scholar
  319. 318.
    Moore, R.A., Sear, J.W., Bullingham, R.E.S., and McQuay, H.J., 1986, Morphine kinetics in renal failure, Adv. Pain Res. Ther. 8:65–72.Google Scholar
  320. 319.
    Ratcliffe, P.J., Sear, J.W., Hand, C.W., and Moore, R.A., 1985, Morphine transport in the isolated perfused rat kidney, Proc EDTA-ERA 22:1109–1114.Google Scholar
  321. 320.
    Chan, K., Tse, J., Jennings, F., and Orme, M.L. ’E., 1987, Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction, J. Clin. Pharmacol. 27:516–522.PubMedGoogle Scholar
  322. 321.
    Chan, G.L.C. and Matzke, G.R., 1987, Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics, Drugs Intell. Clin. Pharm. 21:773–783.Google Scholar
  323. 322.
    Clissold, S.P., 1986, Paracetamol and phenacetin, Drugs 32(Suppl 4)46–59.PubMedGoogle Scholar
  324. 323.
    Clissold, S.P., 1986, Aspirin and related derivatives of salicylic acid, Drugs 32(Suppl 4)8–26.PubMedGoogle Scholar
  325. 324.
    Williams, M.E., Weinblatt, M., Rosa, R.M., Griffin, V.L., Goldlust, M.B., Shang, S.F., Harrison, L.I., and Brown, R.S., 1986, Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis, Clin. Pharmacol. Ther. 39:420–424.PubMedGoogle Scholar
  326. 325.
    Bonney, S.L., Northington, R.S., Hedrich, D.A., and Walker, B.R., 1986, Renal safety of two analgesics used over the counter: Ibuprofen and aspirin, Clin. Pharmacol. Ther. 40:373–377.PubMedGoogle Scholar
  327. 326.
    Brogden, R.N., 1986, Non-steroidal anti-inflammatory analgesics other than salicylates, Drugs 32 (Suppl 4)27–45.PubMedGoogle Scholar
  328. 327.
    Wong, D.G., Spence, J.D., Lamki, L., Freeman, D., and McDonald, J.W.D., 1986, Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics, Lancet 1:997–1002.PubMedGoogle Scholar
  329. 328.
    Skinner, M.H., Mutterperl, R., and Zeitz, H.J., 1987, Sulindac inhibits bumetanide-induced sodium and water excretion, Clin. Pharmacol. Ther. 42:542–546.PubMedGoogle Scholar
  330. 329.
    Radack, K.L., Deck, C.C., and Bloomfield, S.S., 1987, Ibuprofen interferes with the efficacy of antihypertensive drugs, Ann. Intern. Med. 107:628–635.PubMedGoogle Scholar
  331. 330.
    Toto, R.D., Anderson, S.A., Brown-Cartwright, D., Kokko, J.P., and Brater, D.C., 1986, Effects of acute and chronic dosing of NSAIDs in patients with renal insufficiency, Kidney Int. 30: 760–768.PubMedGoogle Scholar
  332. 331.
    Whelton, A., LaFrance, N., Spilman, P.S., Stout, R.L., Drew, H., Watson, A.J., Hermann, J., and Klassen, D., 1986, A prospective, ramdomized, cross-over study of the renal effects of ibuprofen, piroxicam, and sulindac in chronic renal impairment, Proc. Am. Soc. Nephrol. 19:67a (Abstract).Google Scholar
  333. 332.
    Sethi, K., Jain, R., and Malhotra, S., 1986, Effects of long-term sulindac therapy in chronic renal failure, Proc. Am. Soc. Nephrol. 19:60a (Abstract).Google Scholar
  334. 333.
    Gibson, R.P., Dobrinska, M.R., Lin, J.H., Entwistle, L.A., and Davies, R.O., 1987, Biotransformation of sulindac in end-stage renal disease, Clin. Pharmacol. Ther. 42:82–88.PubMedGoogle Scholar
  335. 334.
    Klassen, D., Stout, R.L., Spilman, P.S., and Whelton, A., 1986, Kinetics of sulindac and its metabolites in chronic renal insufficiency, J. Clin. Pharmacol. 26:553.Google Scholar
  336. 335.
    Lynch, S. and Brogden, R.N., 1986, Etodolac. A preliminary review of its pharmacodynamic activity and therapeutic use, Drugs 31:288–300.PubMedGoogle Scholar
  337. 336.
    Shand, D.G., Epstein, C., Kinberg-Calhoun, J., Mullane, J.F., and Sanda, M., 1986, The effect of etodolac administration on renal function in patients with arthritis, J. Clin. Pharmacol. 26:269–274.PubMedGoogle Scholar
  338. 337.
    Verbeeck, R. K., Richardson, C. J., and Blocka, K. L. N., 1986, Clinical pharmacokinetics of piroxicam, J. Rheumatol. 13:789–796.PubMedGoogle Scholar
  339. 338.
    Gonzalez, J.P. and Todd, P.A., 1987, Tenoxicam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, Drugs 34:289–310.PubMedGoogle Scholar
  340. 339.
    Horber, F.F., Guenter, T.W., Weidekamm, E., Heizmann, P., Descoeudres, C., and Frey, F.J., 1986, Pharmacokinetics of tenoxicam in patients with impaired renal function, Eur. J. Clin. Pharmacol. 29:697–701.PubMedGoogle Scholar
  341. 340.
    Todd, P.A. and Beresford, R., 1986, Pirprofen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, Drugs 32:509–537.PubMedGoogle Scholar
  342. 341.
    O’Brien, W.M. and Bagby, G.F., 1987, Carprofen: A new nonsteroidal antiinflammatory drug, Pharmacotherapy 7:16–24.PubMedGoogle Scholar
  343. 342.
    Kantor, T.G., 1986, Ketoprofen: A review of its pharmacologic and clinical properties, Pharmacotherapy 6:93–103.PubMedGoogle Scholar
  344. 343.
    Clissold, S.P. and Beresford, R., 1987, Proquazone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases and pain states, Drugs 33:478–502.PubMedGoogle Scholar
  345. 344.
    Mangan, F.R., Flack, J.D., and Jackson, D., 1987, Preclinical overview of nabumetone, Am. J. Med 83(Suppl 4B)6–10.PubMedGoogle Scholar
  346. 345.
    Boelaert, J.R., Jonnaert, H.A., Daneels, R.F., Schurgers, M.L., Thawley, A.R., Undre, N.A., and Cooper, D.L., 1987, Nabumetone pharmacokinetics in patients with varying degrees of renal impairment, Am. J. Med. 83(Suppl 4B) 107–109.PubMedGoogle Scholar
  347. 346.
    Skoutakis, V.A., Acchiardo, S.R., Carter, C.A., Wojciechowski, N.J., Straughn, A.B., and Meyer, M.C., 1986, Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal disease, Drug Intell. Clin. Pharm. 20:956–960.PubMedGoogle Scholar
  348. 347.
    Boiskin, I., Saven, A., Mendez, M., and Raja, R.M., Indomethacin and the nephrotic syndrome, Ann. Intern. Med. 106:776–777.Google Scholar
  349. 348.
    Schwartzman, M. and D’Agati, V., 1987, Spontaneous relapse of naproxen-related nephrotic syndrome, Am. J. Med. 82:329–332.PubMedGoogle Scholar
  350. 349.
    Sennesael, J., Van Den Houte, K., and Verbeelen, D., 1986, Reversible membranous glomerulonephritis associated with ketoprofen, Clin. Nephrol. 26:213–215.PubMedGoogle Scholar
  351. 350.
    Henann, N.E. and Morales, J.R., 1986, Suprofen-induced acute renal failure, Drug Intell. Clin. Pharm. 20:860–862.PubMedGoogle Scholar
  352. 351.
    Henann, J.E., Morales, J.R., 1987, Suprofen-induced acute renal failure revisited, Drug Intell. Clin. Pharm. 21:69–70.PubMedGoogle Scholar
  353. 352.
    Hart, D., Ward, M., and Lifschitz, M.D., 1987, Suprofen-related nephrotoxicity, Ann. Intern. Med. 106:235–238.PubMedGoogle Scholar
  354. 353.
    Wolfe, S.M., 1987, Suprofen-induced transient flank pain and renal failure, N. Engl. J. Med. 316: 1025.PubMedGoogle Scholar
  355. 354.
    Snyder, S. and Teehan, B.P., Suprofen and renal failure, Ann. Intern. Med. 106:776.Google Scholar
  356. 355.
    Murrell, G.A.C. and Rapeport, W.G., 1986, Clinical pharmacokinetics of allopurinol, Clin. Pharmacol. 11:343–353.Google Scholar
  357. 356.
    Kuncl, R.W., Duncan, G., Watson, D., Alderson, K., Rogawski, M.A., and Peper, M., 1987, Colchicine myopathy and neuropathy, N. Engl. J. Med. 316:1562–1568.PubMedGoogle Scholar
  358. 357.
    Levin, V.A., 1986, Clinical anticancer pharmacology: Some pharmacokinetic considerations, Cancer Treatment Rev. 13:61–76.Google Scholar
  359. 358.
    Anon., 1987, Cancer chemotherapy, Med. Lett.29:29–36.Google Scholar
  360. 359.
    Clark, P.I. and Slevin, M.L., 1987, The clinical pharmacology of etoposide and teniposide, Clin. Pharmacol. 12:223–252.Google Scholar
  361. 360.
    D’lncalci, M., Rossi, C., Zucchetti, M., Urso, R., Cavalli, F., Mangioni, C., Willems, Y., and Sessa, C., 1986, Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function, Cancer Res. 46:2566–2571.Google Scholar
  362. 361.
    Belldegrun, A., Webb, D.E., Austin, H.A. Ill, Steinberg, S.M., White, D.E., Linehan, W.M., and Rosenberg, S.A., 1987, Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer, Ann. Intern. Med. 106:817–822.PubMedGoogle Scholar
  363. 362.
    Textor, S.C., Margolin, K., Blayney, D., Carlson, J., and Doroshow, J., 1987, Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man, Am. J. Med. 83:1055–1061.PubMedGoogle Scholar
  364. 363.
    Wartha, R., Damjantschitsch, M., Damjanschitsch, V., Kuchl, J., and Gekle, D., 1985, Nephrotoxicity of high dose methotrexate therapy—A long-term follow-up study in five juvenile patients with osteosarcoma, Proc. EDTA-ERA 22:1025–1031.Google Scholar
  365. 364.
    Evans, W.E. and Christensen, M.L., 1985, Drug interactions with methotrexate, J. Rheumatol. 12(Suppl 12) 15–20.Google Scholar
  366. 365.
    Salemans, J., Hoitsma, A.J., De Abreu, R.A., de Vos, D., and Koene, R.A.P., 1987, Pharmacokinetics of azathioprine and 6-mercaptopurine after oral administration of azathioprine, Clin. Trans. 1:217–221.Google Scholar
  367. 366.
    Chan, G.L.C., Canafaz, D.M., and Johnson, C.A., 1987, The therapeutic use of azathioprine in renal transplantation, Pharmacotherapy 7(5) 165–177.PubMedGoogle Scholar
  368. 367.
    Reilly, C.S. and Nimmo, W.S., 1987, New intravenous anaesthetics and neuromuscular blocking drugs. A review of their properties and clinical use, Drugs 34:98–135.PubMedGoogle Scholar
  369. 368.
    Mongin-Long, D., Chabrol, B., Baude, C., Ville, D., Renaudie, M., Dubernard, J.M., and Moskovtchenko, J.F., 1986, Atracurium in patients with renal failure, Br. J. Anaesth. 58:44S–48S.PubMedGoogle Scholar
  370. 369.
    Miller, R.D., 1986, Pharmacokinetics of atracurium and other nondepolarizing neuromuscular blocking agents in normal patients and those with renal or hepatic dysfunction, Br. J. Anaesth. 58: 11S–13S.PubMedGoogle Scholar
  371. 370.
    Bencini, A.F., Scaf, A.H.J., Sohn, Y.J., Meistelman, C., Lienhart, A., Kersten, U.W., Schwarz, S., and Agoston, S., 1986, Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure, Anesth. Analg. 65:245–251.PubMedGoogle Scholar
  372. 371.
    Gramstad, L., 1987, Atracurium, vecuronium and pancuronium in end-stage renal failure, Br. J. Anaesth. 59:995–1003.PubMedGoogle Scholar
  373. 372.
    Mujais, S.K., 1986, Transport and renal effects of general anesthetics, Semin. Nephrol. 6(3)251–258.PubMedGoogle Scholar
  374. 373.
    Abu-Romch, S.H., Al-Nakib, B., and Johny, K.V., 1987, Acute renal failure following halothane anesthesia, Clin. Nephrol. 27:213–215.Google Scholar
  375. 373a.
    Ward, A., Chaffman, M.O., and Sorkin, E.M., 1986, Dantrolen. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity, Drugs 32:130–168.PubMedGoogle Scholar
  376. 374.
    Gupta, S.K., Legg, B., Solomon, L.R., Johnson, R.W.G., and Rowland, M., 1987, Pharmacokinetics of cyclosporine: Influence of rate of constant intravenous infusion in renal transplant patients, Br. J. Clin. Pharmacol. 24:519–526.PubMedGoogle Scholar
  377. 375.
    Öst, L., 1987, Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients, Transplantation 44:533–535.PubMedGoogle Scholar
  378. 375a.
    Landgraf, R., Landgraft-Leurs, M.M.C., Nusser, J., Hillebrand, G., Illner, W-D., Abendroth, D., and Land, W., 1987, Effect of somatostatin analogue (SMS201-995) on cyclosporine levels, Transplantation 44:724–725.PubMedGoogle Scholar
  379. 376.
    Balant-Gorgia, A.E. and Balant, L., 1987, Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring, Clin. Pharmacol. 13:65–90.Google Scholar
  380. 377.
    Benfield, P., Heel, R.C., and Lewis, S.P., 1986, Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness, Drugs 32:481–508.PubMedGoogle Scholar
  381. 378.
    Sommi, R.W., Crismon, M.L., and Bowden, C.L., 1987, Fluoxetine: A serotonin-specific, second-generation antidepressant, Pharmacotherapy 7:1–15.PubMedGoogle Scholar
  382. 379.
    Lieberman, J.A., Cooper, T.B., Suckow, R.F., Steinberg, H., Borenstein, M., Brenner, R., and Kane, J.M., 1985, Tricyclic antidepressant drug and metabolite levels in chronic renal failure, Clin. Pharmacol. Ther. 37:301–307.PubMedGoogle Scholar
  383. 380.
    Goa, K.L. and Ward, A., 1986, Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic, Drugs 32:114–129.PubMedGoogle Scholar
  384. 381.
    Ochs, H.R., Greenblatt, D.J., and Kniichel, M., 1986, Effect of cirrhosis and renal failure on the kinetics of clotiazepam, Eur. J. Clin. Pharmacol. 30:89–92.PubMedGoogle Scholar
  385. 382.
    Mallette, L.W. and Eichhorn, E., 1986, Effects of lithium carbonate on human calcium metabolism, Arch. Intern. Med. 146:770–776.PubMedGoogle Scholar
  386. 383.
    Aquilonius, S.M. and Hartvig, P., 1986, Clinical pharmacokinetics of cholinesterase inhibitors, Clin. Pharmacokinetics 11:236–249.Google Scholar
  387. 384.
    Cedarbaum, J.M., 1987, Clinical pharmacokinetics of anti-parkinsonian drugs, Clin. Pharmacokinetics 13:141–178.Google Scholar
  388. 385.
    Garg, D.C., Baltodano, N., Jallad, N.S., Perez, G., Oster, J.R., Eshelman, F.N., and Weidler, D.J., 1986, Pharmacokinetics of ranitidine in patients with renal failure, J. Clin. Pharmacol. 26: 286–291.PubMedGoogle Scholar
  389. 386.
    Takabatake, T., Ohta, H., Yamamoto, Y., Ishida, Y., Hara, H., Nakamura, S., Ushiogi, Y., Satoh, S., and Hattori, N., 1986, Pharmacokinetics of TZU-0460, a new H2-Receptor antagonist, in patients with impaired renal function, Eur. J. Clin. Pharmacol. 30:709–712.PubMedGoogle Scholar
  390. 387.
    Campoli-Richards, D.M. and Clissold, S.P., 1986, Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome, Drugs 32:197–221.PubMedGoogle Scholar
  391. 388.
    Halstenson, C.E., Abraham, P.A., Opsahl, J.A., Chremos, A.N., Keane, W.F., and Matzke, G.R., 1987, Disposition of famotidine in renal insufficiency, J. Clin. Pharmacol. 27:782–787.PubMedGoogle Scholar
  392. 389.
    Naesdal, J., Andersson, T., Bodemar, G., Larsson, R., Regårdh, C-G., Skånberg, I., and Walan, A., 1986, Pharmacokinetics of [14C]omeprazole in patients with impaired renal function, Clin. Pharmacol. Ther. 40:344–351.PubMedGoogle Scholar
  393. 390.
    Illingworth, D.R., 1986, Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia, Clin. Pharmacol. Ther. 40:338–343.PubMedGoogle Scholar
  394. 391.
    Anon., 1987, Lovastatin for hypercholesterolemia, Med. Lett. 29:99–102.Google Scholar
  395. 392.
    Golper, T.A., Illingworth, D.R., Morris, C.D., and Bennett, W.M., 1989, Lovostatin in the therapy of nephrotic hyperlipemia. Am. Journ. Kid. Dis. (in press).Google Scholar
  396. 393.
    Hunninghake, D.B. and Hibbard, D.M., 1986, Influence of time intervals for cholestyramine dosing on the absorption of hydrochlorothiazide, Clin. Pharmacol. Ther. 39:329–334.PubMedGoogle Scholar
  397. 394.
    Monk, J.P. and Todd P.A., 1987, Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia, Drugs 33:539–576.PubMedGoogle Scholar
  398. 395.
    Chapman, M.J., 1987, Pharmacology of fenofibrate, Am. J. Med. 83:21–25.PubMedGoogle Scholar
  399. 396.
    Blane, G.F., 1987, Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives, Am. J. Med. 83:26–36.PubMedGoogle Scholar
  400. 397.
    Van Acker, B.A.C., Bilo, H.J.G., Snijders, P., Van Bronswijk, H., Rustemeijer, C., Oe, P.L., and Donker, A.J.M., 1986, Omega-3 polyunsaturated fatty acids improve lipid profile and lower blood viscosity in CAPD patients, Proc. Am. Soc. Nephrol. 19:98a (Abstract).Google Scholar
  401. 398.
    Ferner, R.E. and Chaplin, S., 1987, The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs, Clin. Pharmacokinetics 12:379–401.Google Scholar
  402. 399.
    Pearson, J.G., Antal, E.J., Raehl, C.L., Gorsch, H.K., Craig, W.A., Albert, K.S., and Welling, P.G., 1986, Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function, Clin. Pharmacol. Ther. 39:318–324.PubMedGoogle Scholar
  403. 400.
    Benfield, P., 1986, Aldose reductase inhibitors and late complications of diabetes, Drugs 32:43–55.PubMedGoogle Scholar
  404. 401.
    Brogden, R.N. and Heel, R.C., 1987, Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use, Drugs 34:350–371.PubMedGoogle Scholar
  405. 402.
    Holford, N.H.G., 1986, Clinical pharmacokinetics and pharmacodynamics of warfarin, Clin. Pharmacokinetics 11:483–504.Google Scholar
  406. 403.
    Krstenansky, P.M. and Cluxton, R.J., Jr., 1987, Astemizole: A long-acting, nonsedating antihistamine, Drug Intell. Clin. Pharm. 21:947–952.PubMedGoogle Scholar
  407. 404.
    Ganeval, D., Fischer, A.M., Barre, J., Pertuiset, N., Dautzenberg, M.D., Jungers, P., and Houin, G., 1986, Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin Kdependent clotting factors, Clin. Nephrol. 25:75–80.PubMedGoogle Scholar
  408. 405.
    Ward, A. and Clissold, S.P., 1987, Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy, Drugs 34:50–97.PubMedGoogle Scholar
  409. 406.
    Silver, M.R. and Kroboth, P.D., 1987, Pentoxifylline in end-stage renal disease, Drug Intell. Clin. Pharm. 21:976–978.PubMedGoogle Scholar
  410. 407.
    Saltiel, E. and Ward, A., 1987, Ticlopidine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states, Drugs 34:222–262.PubMedGoogle Scholar
  411. 408.
    Clissold, S.P., Lynch, S., and Sorkin, E.M., 1987, Buflomedil: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases, Drugs 33:430–460.PubMedGoogle Scholar
  412. 409.
    Gregov, D., Jenkins, A., Siebert, D., Rodgers, S., Duncan, B., Bochner, F., and Lloyd, J., 1987, Dipyridamole: Pharmacokinetics and effects on aspects of platelet function in man, Br. J. Clin. Pharmacol. 24:425–434.PubMedGoogle Scholar
  413. 410.
    Goa, K.L. and Monk, J.P., 1987, Enprostil. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease, Drugs 34:539–559.PubMedGoogle Scholar
  414. 411.
    Gonzalez, J.P. and Brogden, R.N., 1987, Nedocromil sodium. A preliminary review of its pharmacodynamic and pharamcokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airways disease, Drugs 34:560–577.PubMedGoogle Scholar
  415. 412.
    Cloyd, J.C., Snyder, B.D., Cleeremans, B., and Bundlie, S.R., 1985, Mannitol pharmacokinetics and serum osmolality in dogs and humans, J. Pharmacol. Exp. Ther. 236:301–306.Google Scholar
  416. 413.
    DeBroe, M. E, Van de Vyver, F.L., D’Haese, P.C., Visser, W.J., Elseviers, M.M., and Wedeen, R.P., 1986, Bone lead and the role of lead in renal disease, Proc. Am. Soc. Nephrol. 19: 39a (Abstract).Google Scholar
  417. 414.
    Osterloh, J. and Becker, C.E., 1986, Pharmacokinetics of CaNa2 EDTA and chelation of lead in renal failure, Clin. Pharmacol. Ther. 40:686–93.PubMedGoogle Scholar
  418. 415.
    Shusterman, N., Strom, B.L., Murray, T.G., Morrison, G., West, S.L., and Maislin, G., 1987, Risk factors and outcome of hospital-acquired acute renal failure, Am. J. Med. 83:65–71.PubMedGoogle Scholar
  419. 416.
    Lämeire, N., Matthys, E., Vanholder, R., De Keyser, K., Pauwels, W., Nachtergaele, H., Lambrecht, L., and Ringoir, S., 1987, Causes and prognosis of acute renal failure in elderly patients, Nephrol. Dial. Transplant. 2:316–322.PubMedGoogle Scholar
  420. 417.
    Handa, S.P., 1986, Drug-induced acute interstitial nephritis: Report of 10 cases, Can. Med. Assoc. J. 135:1278–1281.Google Scholar
  421. 418.
    Cannon-Babb, M.L. and Schwartz, A.B., 1986, Drug-induced hyperkalemia, Hosp. Pract. 99- 127.Google Scholar
  422. 419.
    Cruz, C., Hricak, H., Samhouri, F., Smith, R.F., Eyler, W.R., and Levin, N.W., 1986, Contrast media for angiography: Effect on renal function, Radiology 158:109–112.PubMedGoogle Scholar
  423. 420.
    Taliercio, C.P., Vlietstra, R.E., Fisher, L.D., and Burnett, J.C., 1986, Risks for renal dysfunction with cardiac angiography, Ann. Intern. Med. 104:501–504.PubMedGoogle Scholar
  424. 421.
    Fairley, S. and Ihle, B.U., 1986, Thrombotic microangiopathy and acute renal failure associated with arteriography, Br. Med. J. 293:922–923.Google Scholar
  425. 422.
    Morris, T.W. and Fischer, H.W., 1986, The pharmacology of intravascular radiocontrast media, Annu. Rev. Pharmacol. Toxicol. 26:143–160.PubMedGoogle Scholar
  426. 423.
    Bourin, M., Laporte, V., Guenzet, J., Langlois, S., Pengloan, J., and Rouleau, P., 1986, Pharmacokinetic study of ioxaglate, a low osmolality contrast medium, in patients with renal failure, Int. J. Clin. Pharmacol. Ther. Toxicol. 24:614–621.PubMedGoogle Scholar
  427. 424.
    Albrechtsson, U., Hultberg, B., Larusdottir, H, and Norgren, L., 1985, Nephrotoxicity of ionic and non-ionic contrast media in aorto-femoral angiography, Acta Radiol. Diagnosis 26:615–618.Google Scholar
  428. 425.
    Cavaliere, G., Arrigo, G., D’Amico, G., Bernasconi, P., Schiavina, G., Dellafiore, L., and Vergnaghi, D., 1987, Tubular nephrotoxicity after intravenous urography with ionic high-osmolal and nonionic low-osmolal contrast media in patients with chronic renal insufficiency, Nephron 46: 128–133.PubMedGoogle Scholar
  429. 426.
    Cedgard, S., Herlitz, H., Geterud, K., Attmam, P-O., and Aurell, M., 1986, Acute renal insufficiency after administration of low-osmolar contrast media, Lancet 2:1281.PubMedGoogle Scholar
  430. 427.
    Evans, J.R. and Cutler, R.E., 1987, Low-osmolar radiocontrast agents and nephrotoxicity, Dial. Transplant 16:504–508.Google Scholar
  431. 428.
    Thompson, W.M., 1986, New intravascular contrast material, Arch. Intern. Med. 146:1688.PubMedGoogle Scholar
  432. 429.
    Schwab, S.J., Hlatky, M., Morris, K., Mark, D., Davidson, C., Skelton, T., and Bashore, T., 1987, Contrast nephrotoxicity: A prospective randomized trial of ionic versus non-ionic radiographic contrast, Proc. Am. Soc. Nephrol. 20:61a (Abstract).Google Scholar
  433. 430.
    Katzberg, R.W., Pabico, R.C., Morris, T.W., Hayakawa, K., McKenna, B.A., Panner, B.J., Ventura, J.A., and Fischer, H.W., 1986, Effects of contrast media on renal function and subcellular morphology in the dog, Invest. Radiol. 21:64–70.PubMedGoogle Scholar
  434. 431.
    Bently, M.D., Vanhoutte, V., Schryver, S.M., Romero, J.C., and Vanhoutte, P.M., 1986, Contraction of isolated canine renal arteries induced by the radiocontrast medium, sodium/ meglumine diatrizoate, Proc. Am. Soc. Nephrol. 19:263a (Abstract).Google Scholar
  435. 432.
    Bakris, G.L., Jones, J., and Burnett, J.C., Jr., 1986, Suppression of oxygen free radicals (FR) attenuates the radiocontrast medium (RCM)-induced decline in glomerular filtration rate (GFR), Proc. Am. Soc. Nephrol. 19:206a (Abstract).Google Scholar
  436. 433.
    Humes, H.D., Hunt, D.A., and White, M.D., 1987, Direct toxic effect of the radiocontrast agent diatrizoate on renal proximal tubule cells, Am. J., Physiol. 252(Renal Fluid Electrolyte Physiol. 21):F246–F255.Google Scholar
  437. 434.
    Scanu, P., de Ligny, H., and Ryckelynck, J.P., 1987, Reversible acute renal insufficiency with combination of enalapril and diuretics in a patient with a single renal-artery stenosis, Nephron 45: 321–322.PubMedGoogle Scholar
  438. 435.
    Funck-Brentano, C., Chatellier, G., and Alexandre, J-M., 1986, Reversible renal failure after combined treatment with enalapril and fursemide in a patient with congestive heart failure, Br. Heart J. 55:596–598.PubMedGoogle Scholar
  439. 436.
    Andreucci, V.E., Conte, G., and Dal Canton, A., 1986, The causal role of salt depletion in acute depletion in acute renal failure due to captopril in hypertensive patients with a single kidney and renal artery stenosis, Postgrad. Med. J. 62:43a (Abstract).Google Scholar
  440. 437.
    Cleland, J.G.F., Dargie, H.J., Gillen, G., Robertson, I., East, B.W., Ball, S.G., Morton, J.J., and Robertson, J.I.S., 1986, Captopril in heart failure: A double-blind study of the effects on renal function, J. Cardiovasc. Pharmacol. 8:700–706.PubMedGoogle Scholar
  441. 438.
    Packer, M., Lee, W.H., Medina, N., Yushak, M., and Kessler, P.D., 1987, Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure, Ann. Intern. Med. 106:346–354.PubMedGoogle Scholar
  442. 439.
    Postma, C.T., Hoefnagels, W.H.L., Thien, T.H., and DeBoo, T.H., 1987, ACE inhibitors, atheroma, and renal function, Lancet 2:1080–1081.PubMedGoogle Scholar
  443. 440.
    Michel, J-B., Nochy, D., Choudat, L., Dussaule, J-C., Philippe, M., Chastang, C., Corvol, P., and Menard, J., 1987, Consequences of renal morphologic damage induced by inhibition of converting enzyme in rat renovascular hypertension, Lab. Invest. 57:402–411.PubMedGoogle Scholar
  444. 441.
    Linton, A.L., 1987, AG-ARF, Renal Failure 10:61–62.PubMedGoogle Scholar
  445. 442.
    Editorial, 1986, Aminoglycoside toxicity, Lancet 2:670–671.Google Scholar
  446. 443.
    Kapusnik, J.E. and Sande, M.A., 1986, Novel approaches for the use of aminoglycosides: The value of experimental models, J. Antimicrob. Chemother. 17:7–10.PubMedGoogle Scholar
  447. 444.
    Wood, C.A., Norton, D., Kohlhepp, S., Kohnen, P., Bennett, W., Porter, G., Houghton, D. Brummett, R., and Gilbert, D., 1988, Influence of tobramycin dosing regimen on nephrotoxicity, ototoxicity and antibacterial efficacy in a rat model of subcutaneous abcess, J. Infect. Dis. 158:13–22.PubMedGoogle Scholar
  448. 445.
    DeBroe, M.E., Giuliano, R.A., and Verpooten, G.A., 1986, Choice of drug and dosage regimen. Two important risk for aminoglycoside nephrotoxicity, Am. J. Med. 80:115–118.Google Scholar
  449. 446.
    Bergeron, M.G. and Marois, Y., 1986, Benefit from high intrarenal levels of gentamicin in the treatment of E. coli pyelonephritis, Kidney Int. 30:481–487.PubMedGoogle Scholar
  450. 447.
    Meyer, R.D., 1986, Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides, Am. J. Med. 80:119–125.PubMedGoogle Scholar
  451. 448.
    Moore, R.D., Smith, C.R., and Lietman, P.S., 1986, Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides, Am. J. Med. 80:1093–1097.PubMedGoogle Scholar
  452. 449.
    Sawyers, C.L., Moore, R.D., Lerner, S.A., and Smith, C.R., 1986, A model for predicting nephrotoxicity in patients treated with aminoglycosides, J. Infect. Dis. 153:1062–1068.PubMedGoogle Scholar
  453. 450.
    Bernstein, J.M., Gorse, G.J., Linzmayer, I., Pegram, P.S., Levin, R.D., Brummett, R.E., Markowitz, N., Saravolatz, L.D., and Lorber, R.R., 1986, Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients, Arch. Intern. Med. 146:2329–2234.PubMedGoogle Scholar
  454. 451.
    Lerner, S.A., Schmitt, B.A., Seligsohn, R., and Matz, G.J., 1986, Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin, Am. J. Med. 80:98–104.PubMedGoogle Scholar
  455. 452.
    Mandal, A.K., Mize, G.N., and Birnbaum, D.B., 1987, Transmission electron 8microscopy of urinary sediment in aminoglycoside nephrotoxicity, Renal Failure 10:63–81.PubMedGoogle Scholar
  456. 453.
    Steiner, R.W. and Omachi, A.S., 1986, A Bartter’s-like syndrome from capreomycin, and a similar gentamicin tubulopathy, Am. J. Kidney Dis. 8:245–249.Google Scholar
  457. 454.
    Schacht, J. and Van De Water, T., 1986, Uptake and accumulation of gentamicin in the developing inner ear of the mouse in vitro, Biochem. Pharm. 35:2843–2845.PubMedGoogle Scholar
  458. 455.
    Tran Ba Huy, P., Bernard, P., and Schacht, J., 1986, Kinetics of gentamicin uptake and release in the rat, J. Clin. Invest. 77:1492–1500.PubMedGoogle Scholar
  459. 456.
    Dulon, D., Aran, J-M., Zajic, G., and Schacht, J., 1986, Comparative uptake of gentamicin, netilmicin, and amikacin in the guinea pig cochlea and vestibule, Antimicrob. Agents Chemother. 30:96–100.PubMedGoogle Scholar
  460. 457.
    Tulkens, P.M., 1986, Experimental studies on nephrotoxicity of aminoglycosides at low doses, Am. J. Med. 80:105–114.PubMedGoogle Scholar
  461. 458.
    Nassaberger, L., Bergstrand, A., and DePierre, J.W., 1987, Biochemical effects of gentamicin on rat kidney cortex. II. Analytical subfractionation after short-term, high-dose treatment, Exp. Mol. Pathol 46:230–243.Google Scholar
  462. 459.
    Giurgea-Marion, L., Toubeau, G., Laurent, G., Heuson-Stiennon, J.A., and Tulkens, P.M., 1986, Impairment of lysosome-pinocytic vesicle fusion in rat kidney proximal tubules after treatment with gentamicin at low doses, Toxicol Appl Pharmacol 86:271–285.PubMedGoogle Scholar
  463. 460.
    Oshima, M., Hashiguchi, M., Shindo, N., and Shibata, S., 1986, Biochemical mechanisms of aminoglycoside cell toxicity. I. The uptake of gentamicin by cultured skin fibroblasts and the alteration of lysosomal enzyme activities, J. Biochem. 100:1575–1582.PubMedGoogle Scholar
  464. 461.
    Williams, P.S., Hottendorf, G.H., and Bennett, D.B., 1986, Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides, J. Pharmacol Exp. Ther. 237:919–925.PubMedGoogle Scholar
  465. 462.
    Bennett, W.M., Wood, C.A., Kohlhepp, S.J., Kohnen, P.W., Houghton, D.C., and Gilbert, D.N., 1988, Experimental gentamicin nephrotoxicity can be prevented by polyaspartic acid, Kidney Int. 33:353 (Abstract).Google Scholar
  466. 463.
    Ramsammy, L., Josepovitz, C., Lane, B., and Kaloyanides, G.J., 1986, Polyaspartic acid (PAA) protects against gentamicin (G) nephrotoxicity in the rat, Proc. Am. Soc. Nephrol 19:217a (Abstract).Google Scholar
  467. 464.
    Ramsammy, L.S., Josepovitz, C., Ling, K-Y., Lane, B.P., and Kaloyanides, G.J., 1985, Effects of diphenyl-phenylenediamine on gentamicin-induced lipid peroxidation and toxicity in rat renal cortex, J. Pharmacol Exp. Ther. 238:83–88.Google Scholar
  468. 465.
    Marche, P., Olier, B., Girard, A., Fillastre, J-P., and Morin, J-P., 1987, Aminoglycoside-induced alterations of phosphoinositide metabolism, Kidney Int. 31:59–64.PubMedGoogle Scholar
  469. 466.
    Ramsammy, L., Josepovitz, C., and Kaloyanides, G.J., 1987, Gentamicin inhibits generation of inositol phosphates by PTH in primary culture of rabbit proximal tubular cells, Clin. Res. 35:637a (Abstract).Google Scholar
  470. 467.
    Elliott, W.C., Patchin, D.S., and Jones, D.B., 1987, Effect of parathyroid hormone activity on gentamicin nephrotoxicity, J. Lab. Clin. Med. 109:48–54.PubMedGoogle Scholar
  471. 468.
    Ghosh, P. and Chatterjee, S., 1987, Effects of gentamicin on sphingomyelinase activity in cultured human renal proximal tubular cells, J. Biol. Chem. 262:12550–12556.PubMedGoogle Scholar
  472. 469.
    Horio, M., Fukuhara, Y., Orita, Y., Nakanishi, T., Nakahama, H., Moriyama, T., and Kamada, T., 1986, Gentamicin inhibits Na+-dependent D-glucose transport in rabbit kidney brushborder membrane vesicles, Biochim. Biophys. Acta 858:153–160.PubMedGoogle Scholar
  473. 470.
    Mela-Riker, L.M., Widener, L.L., Houghton, D.C., and Bennett, W.M., 1986, Renal mitrochondrial integrity during continuous gentamicin treatment, Biochem. Pharm. 35:979–984.PubMedGoogle Scholar
  474. 471.
    Toubeau, G., Maldague, P., Laurent, G., Vaamonde, C.A., Tulkens, P.M., and Heuson- Stiennon, J.A., 1986, Morphological alterations in distal and collecting tubules of the rat renal cortex after aminoglycoside administration at low doses, Virchows Arch. 51:475–485.Google Scholar
  475. 472.
    Bergeron, M.G., Bergeron, Y., and Marois, Y., 1986, Autoradiography of tobramycin uptake by the proximal and distal tubules of normal and endotoxin-treated rats, Antimicrob. Agents Chemother. 29:1005–1009.PubMedGoogle Scholar
  476. 473.
    Keane, W.F., Welch, R., Gekker, G., and Peterson, P.K., 1987, Mechanism of Escherichia coli α-hemolysin-induced injury to isolated renal tubular cells, Am. J. Pathol. 126:350–357.PubMedGoogle Scholar
  477. 474.
    Bernard, A., Viau, C., Ouled, A., Tulkens, P., and Lauwerys, R., 1986, Effects of gentamicin on the renal uptake of endogenous and exogenous proteins in conscious rats, Toxicol. Appl. Pharmacol. 84:431–438.PubMedGoogle Scholar
  478. 475.
    Cronin, R.E., Brown, D.M., and Simonsen, R., 1986, Protection by thyroxine in nephrotoxic acute renal failure, Am. J. Physiol. 251:F408–F416.PubMedGoogle Scholar
  479. 476.
    Pastoriza-Munoz, E., Josepovitz, C., Ramsammy, L., and Kaloyanides, G.J., 1985, Renal handling of netilmicin in the rat with streptozotocin-induced diabetes mellitus, J. Pharmacol. Exp. Ther. 241:166–173.Google Scholar
  480. 477.
    Watson, A.J., Gimenez, L.F., Klassen, D.K., Stout, R.L., and Whelton, A., 1987, Calcium channel blockade in experimental aminoglycoside nephrotoxicity, J. Clin. Pharmacol. 27:625–627.PubMedGoogle Scholar
  481. 478.
    Pattison, M.E., Lee, S.M., and Logan, J.L., 1986, The protective effect of nitrendipine (N) on gentamicin (G) nephrotoxicity in the rat, Proc. Am. Soc. Nephrol. 19:216a (Abstract).Google Scholar
  482. 479.
    Furuhama, K. and Onodera, T., 1986, The influence of cephem antibiotics on gentamicin nephrotoxicity in normal, acidotic, dehydrated, and unilaterally nephrectomized rats, Toxicol. Appl. Pharmacol. 86:430–436.PubMedGoogle Scholar
  483. 480.
    Bryant, T.E., Ohnishi, A., Hamilton, R., and Branch, R.A., 1987, Influence of salt status and a prophylactic effect of ticarcillin during salt depletion in nephrotoxicity induced by gentamicin in the rat, Clin. Res. 35:9a (Abstract).Google Scholar
  484. 481.
    Keniston, R.C., Cabellon, S. Jr., and Yarbrough, K.S., 1987, Pyridoxal 5’-phosphate as an antidote for cyanide, spermine, gentamicin, and dopamine toxicity: An in vivo rat study, Toxicol. Appl. Pharmacol. 88:433–441.PubMedGoogle Scholar
  485. 482.
    Reynolds, R.D. and Natta, C.L., 1986, Aminophylline and gentamicin-2, Am. J. Clin. Nutr. 43: 636–642.Google Scholar
  486. 483.
    Houghton, D.C., Lee, D., Gilbert, D.N., and Bennett, W.M., 1986, Chronic gentamicin nephrotoxicity. Continued tubular injury with preserved glomerular filtration function, Am. J. Pathol. 123:183–194.PubMedGoogle Scholar
  487. 484.
    Groth, S., Neilsen, H., Sørensen, J.B., Christensen, A.B., Pedersen, A.G., and Rørth, M., 1986, Acute and long-term nephrotoxicity of ds-platinum in man, Cancer Chemother. Pharmacol. 17:191–196.PubMedGoogle Scholar
  488. 485.
    Goren, M.P., Wright, R.K., and Horowitz, M.E., 1986, Cumulative renal tubular damage associated with cisplatin nephrotoxicity, Cancer Chemother. Pharmacol. 18:69–73.PubMedGoogle Scholar
  489. 486.
    Metz, U., Kurschel, E., and Graben, N., 1985, Monitoring renal toxicity of c/s-platinum by urinary enzymes, Proc. EDTA-ERA 22:1087–1090.Google Scholar
  490. 487.
    de Gislain, C., Dumas, M., d’Athis, P., Lautissier, J-L., Escousse, A., and Guerrin, J., 1986, Urinary β2-microglobulin: Early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide, Cancer Chemother. Pharmacol. 18:276–279.PubMedGoogle Scholar
  491. 488.
    Lam, M. and Adelstein, D.J., 1986, Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin, Am. J. Kidney Dis. 8:164–169.PubMedGoogle Scholar
  492. 489.
    De Broe, M.E. and Wedeen, R.P., 1986, Prevention of cisplatin nephrotoxicity, Eur. J. Cancer Clin. Oncol. 22:1029–1031.PubMedGoogle Scholar
  493. 490.
    Nanji, A.A., Stewart, D.J., and Mikhael, N.Z., 1986, Hyperuricemia and hypoalbuminemia predispose to cisplatin-induced nephrotoxicity, Cancer Chemother. Pharmacol. 17:274–276.PubMedGoogle Scholar
  494. 491.
    Reece, P.A., Stafford, I., Russell, J., Khan, M., and Gill, P.G., 1987, Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity, J. Clin. Oncol. 5: 304–309.PubMedGoogle Scholar
  495. 492.
    Gordon, J.A. and Gattone, V.H. II., 1986, Mitochondrial alterations in cisplatin-induced acute renal failure, Am. J. Physiol. 250(Renal Fluid Electrolyte Physiol. 19):F991–F998.PubMedGoogle Scholar
  496. 493.
    Gordon, J.A., Gattone, V.H., II., and Schoolwerth, A.C., 1986, γ-Glutamyl transpeptidase excretion in cisplatin-induced acute renal failure, Am. J. Kidney Dis. 8:18–25.PubMedGoogle Scholar
  497. 494.
    Magil, A.B., Mavichak, V., Wong, N.L.M., Quamme, G. A, Dirks, J.H., and Sutton, R.A.L., 1986, Long-term morphological and biochemical observations in cisplatin-induced hypomagnesemia in rats, Nephron 43:223–230.PubMedGoogle Scholar
  498. 495.
    Dobyan, D.C., 1985, Long-term consequences of ris-platinum-induced renal injury: A structural and functional study, Anat. Rec. 212:239–245.PubMedGoogle Scholar
  499. 496.
    Moel, D.I., Safirstein, R.L., Cohen, R.A., and Penning, J., 1987, The role of prostaglandins in early polyuria induced by cicplatin in the rat, Nephron 46:91–95.PubMedGoogle Scholar
  500. 497.
    Capasso, G., Anastasio, P., Giordano, D., Albarano, L., and DeSanto, N.G., 1987, Beneficial effects of atrial natriuretic factor on cisplatin-induced acute renal failure in the rat, Am. J. Nephrol. 7:228–234.PubMedGoogle Scholar
  501. 498.
    Jones, M.M., Basinger, M.A., Mitchell, W.M., and Bradley, C.A., 1986, Inhibition of cisdiamminedichloroplatinum (II)-induced renal toxicity in the rat, Cancer Chemother. Pharmacol. 17:38–42.PubMedGoogle Scholar
  502. 499.
    Bodenner, D.L., Dedon, P.C., Keng, P.C., Katz, J.C., and Borch, R.F., 1986, Selective protection against a’s-diamminedichloroplatinum (Il)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate, Cancer Res. 46:2751–2755.PubMedGoogle Scholar
  503. 500.
    Von Graffenried, B. and Krupp, P., 1986, Side effects of cyclosporine (Sandimmun) in renal transplant recipients and in patients with autoimmune diseases, Transplant. Proc. 18:876–883.Google Scholar
  504. 501.
    Canadian Multicentre Transplant Study Group, 1988, A randomized clinical trial of cyclosporine in cadaveric renal transplantation, N. Engl. J. Med. 309:809–815.Google Scholar
  505. 502.
    Hall, B.M., Tiller, D.J., Duggin, G.G., Horvath, J.S., Farnsworth, A., May, J., Johnson, J.R., and Shiel, A.G.R., 1985, Post-transplant acute renal failure in cadaver renal recipients treated with cyclosporine, Kidney Int. 28:178–186.PubMedGoogle Scholar
  506. 503.
    Greenberg, A., Egel, J.W., Thompson, M.E., Hardesty, R.L., Griffith, B.P., Bahnson, H.T., Bernstein, R.L., Hastillo, A., Hess, M.L., and Puschett, J.B., 1987, Early and late forms of cyclosporine nephrotoxicity: Studies in cardiac transplant patients, Am. J. Kidney Dis. 9:12–22.PubMedGoogle Scholar
  507. 504.
    Bennett, W., 1985, Basic mechanisms and pathophysiology cyclosporine nephrotoxicity, Transplant. Proc. 17:297–302.Google Scholar
  508. 505.
    Myers, B.D., 1986, Cyclosporine nephrotoxicity, Kidney Int. 30:964–974.PubMedGoogle Scholar
  509. 506.
    Wheatley, H.C., Daltzman, M., Williams, J.W., Miles, D.E., and Hatch, F.E., 1985, Longterm effects of cyclosporine on renal function in liver transplant recipients, Transplantation 43: 641–647.Google Scholar
  510. 507.
    Palestine, A.G., Austin, H.A., Balow, J.E., Antonovych, T.T., Sabnis, S.G., Preuss, H.G., and Nussenblatt, R.B., 1986, Renal histopathologic alterations in patients treated with cyclosporine for uveitis, N. Engl. J. Med. 314:1293–1298.PubMedGoogle Scholar
  511. 508.
    Curtis, J.J., Luke, R.G., Jones, P., Dubovsky, E.V., Whelchel, J.D., and Diethelm, A.G., 1986, Cyclosporine in therapeutic doses increases renal allograft resistance, Lancet 2:477–479.PubMedGoogle Scholar
  512. 509.
    Jackson, N.M., Hsu, C., Visscher, G.E., and Venkatachalam, M.A., and Humes, H.D., 1987, Alterations in renal structure and function in a rat model of cyclosporine nephrotoxicity, J. Pharmacol. Exp. Ther. 242:749–756.PubMedGoogle Scholar
  513. 510.
    Rogers, T.S., Elzinga, L., Bennett, W.M., and Kelley, V.E., 1988, Selective enhancement of thromboxane in macrophages and kidneys in cyclosporine A induced nephrotoxicity. Dietary protection by fish oil, Transplantation 45:153–156.PubMedGoogle Scholar
  514. 511.
    Keusch, G., Gmür, J., Baumgartner, D., Burger, H.R., Largiader, F., and Binswanger, V., 1986, De novo hemolytic uremic syndrome in two renal allograft recipients treated with cyclosporine: Successful therapy with plasmapheresis, Transplant. Proc. 18:1097–1098.Google Scholar
  515. 512.
    Innes, J.T., Cosio, F.G., Mahan, J.D., Nahman, N.S., and Ferguson, R.M., 1986, Cyclosporine enhances endotoxin induced nephrotoxicity in rabbits, Kidney Int. 29:282a (Abstract).Google Scholar
  516. 513.
    Grace, A.A., Barradas, M.A., Mikhailidis, D.P., Jeremy, J.Y., Moorhead, J.F., Sweny, P., and Dandona, P., 1987, Cyclosporine A enhances platelet aggregation, Kidney Int. 32:889–895.PubMedGoogle Scholar
  517. 514.
    Luke, R.G., 1987, Hypertension in renal transplant recipients, Kidney Int. 31:1024–1037.PubMedGoogle Scholar
  518. 515.
    Textor, S.C., Fornan, S.J., Borer, W., and Carlson, J., 1986, Sequential blood pressure hormonal and renal changes during bone marrow transplant recipients with normal renal function, Clin. Res. 34:44a (Abstract).Google Scholar
  519. 516.
    Bellett, M., Cabrol, C., Sassano, P., Leger, P., Corvol, P., and Menard, J., 1985, Systemic hypertension after cardiac transplantation: Effect of cyclosporine on the renin-angiotensin-aldosterone system, Am. J. Cardiol. 56:927–931.Google Scholar
  520. 517.
    Stanek, B., Kovarik, J., Rasoul-Rockenschaub, S., and Silberbauer, K., 1987, Renin-angiotensin- aldosterone system and vasopressin in cyclosporine-treated renal allograft recipients, Clin. Nephrol. 28:186–189.PubMedGoogle Scholar
  521. 518.
    Vellodi, A., Jayatunga, R., and Hugh-Jones, K., 1987, Hemiplegia and focal convulsions as a manifestation of cyclosporine A toxicity, J. Clin. Pharmacol. 27:914–915.PubMedGoogle Scholar
  522. 519.
    Cantarovich, M., Hiesse, C., Lockiec, F., Charpentier, B., and Fries, D., 1987, Confirmation of the interaction between cyclosporine and the calcium channel blocker nicardipine in renal transplant patients, Clin. Nephrol. 28:190–193.PubMedGoogle Scholar
  523. 520.
    Bendz, H., 1985, Kidney function in a selected lithium population, Acta Psychiatr. Scan. 72:451–463.Google Scholar
  524. 521.
    Vaamonde, C.A., Milian, N.E., Magrinat, G.S., Perez, G.O., and Oster, J.R., 1986, Longitudinal evaluation of glomerular filtration rate during long-term lithium therapy, Am. J. Kidney Dis. 8:213–216.Google Scholar
  525. 522.
    Samiy, A.H. and Rosnick, P.B., 1987, Early identification of renal problems in patients receiving chronic lithium treatment, Am. Psychiatry 144:670–672.Google Scholar
  526. 523.
    Jorkasky, D., Amsterdam, J., and Cox, M., 1987, Lithium-induced nephropthy: Final report of a 3-year prospective study, Proc. Int. Soc. Nephrol. 10:17a (Abstract).Google Scholar
  527. 524.
    Walker, R.G., Escott, M., Birchall, I., Dowling, J.P., and Kincaid-Smith, P., 1986, Chronic progressive renal lesions induced by lithium, Kidney Int. 29:875–881.PubMedGoogle Scholar
  528. 525.
    Van Dyke, M., Van Damme-Lombaerts, R., and Proesmans, W., 1985, Neonatal diabetes insipidus due to maternal lithium therapy during pregnancy, Proc. EDTA-ERA 22:1017–1019.Google Scholar
  529. 526.
    Teicher, M.H., Altesman, R.I., Cole, J.O., and Schatzberg, A.F., 1987, Possible nephrotoxic interaction of lithium and metronidazole, JAMA 257:3365–3366.PubMedGoogle Scholar
  530. 527.
    Boton, R., Gaviria, M., and Batlle, D.C., 1987, Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy, Am. J. Kidney Dis. 10:329–345.PubMedGoogle Scholar
  531. 528.
    Bach, P.H. and Bridges, J.W., 1986, Chemically induced renal papillary necrosis and upper urothelial carcinoma. Part 1, CRC Crit. Rev. Toxicol. 15:217–329.Google Scholar
  532. 529.
    Dubach, U.C., 1985, Analgesic nephropathy, Proc. EDTA-ERA 222:977–983.Google Scholar
  533. 530.
    Burkart, J.M. and Buckalew, V.M., Nephropathy (N) associated with habitual ingestion of acetaminophen (AC), Proc. Am. Soc. Nephrol. 19:33a (Abstract).Google Scholar
  534. 531.
    Segasothy, M., Suleiman, A.B., Puvaneswary, M., and Rohana, A., 1987, Paracetamol: A cause for analgesic nephropathy (AN) and end-stage renal failure (ESRF), Proc. Int. Cong. Nephrol. 10: 32a (Abstract).Google Scholar
  535. 532.
    Kyle, M.E. and Kocsis, J.J., 1986, The effect of mixed function oxidase induction and inhibition on salicylate-induced nephrotoxicity in male rats, Toxicol. Appl. Pharmacol. 84:241–249.PubMedGoogle Scholar
  536. 532a.
    McCredie, M., Stewart, J.H., Carter, J.J., Turner, J., and Mahony, J.F., 1986, Phenacetin and papillary necrosis: Independent risk factors for renal pelvic cancer, Kidney Int. 30:81–84.PubMedGoogle Scholar
  537. 532b.
    Lornoy, W., Becaus, I., DeVleeschouwer, M., Morelle, V., Fonteyne, E., Thienpont, L., and Mestdagh, J., 1986, Renal cell carcinoma, a new complication of analgesic nephropathy, Lancet 1:1271–1272.PubMedGoogle Scholar
  538. 533.
    Schwartz, A., Kraft, D., Keller, F., Meyer-Sabellek, W., Gawlik, D., and Offermann, G., 1985, Analgesic nephropathy and aluminum toxicity, Proc. EDTA-ERA 22:997–1001.Google Scholar
  539. 534.
    Dunn, M.J. and Patrono, C., eds., 1986, Sympmosium: Renal effects of nonsteroidal antiinflammatory drugs, Am. J. Med. 81:August 25.Google Scholar
  540. 535.
    Epstein, M., ed., 1986, Symposium: Prostaglandins and the kidney. Am. J. Med. 80:January 17.Google Scholar
  541. 536.
    D’Angio, R.G., 1987, Nonsteroidal antiinflammatory drug-induced renal dysfunction related to inhibition of renal prostaglandins, Drug. Intell. Clin. Pharm. 21:954–960.PubMedGoogle Scholar
  542. 537.
    Hart, D. and Lifschitz, M.D., 1987, Renal physiology of the prostaglandins and the effects of nonsteroidal anti-inflammatory agents on the kdiney, Am. J. Nephrol. 7:408–418.PubMedGoogle Scholar
  543. 538.
    L’E Orme, M., 1986, Non-steroidal antiinflammatory drugs and the kidney, Br. Med. J. 292: 1621–1622.Google Scholar
  544. 539.
    Kleinknecht, D., Landais, P., and Goldfarb, B., 1986, Analgesic and nonsteroidal antiinflammatory drug-associated acute renal failure: A prospective collaborative study, Clin. Nephrol. 25:275–281.PubMedGoogle Scholar
  545. 540.
    Bock, H.A., Frölich, J.C., Ritz, R., and Brunner, F.P., 1986, Effects of intravenous aspirin on prostaglandin synthesis and kidney function in intensive care patients, Nephrol. Dial. Transplant. 1:164–169.PubMedGoogle Scholar
  546. 541.
    Unsworth, J., Sturman, S., Lunec, J., and Blake, D., 1987, Renal impairment associated with non-steroidal antiinflammatory drugs, Ann. Rheum. Dis. 46:233–236.PubMedGoogle Scholar
  547. 542.
    Sipilä, R., Skrifvars, B.O., and Törnroth, T., 1986, Reversible nonoliguric impairment of renal function during azapropazone treatment, Scand. J. Rhemunatol. 15:23–26.Google Scholar
  548. 543.
    Abraham, P.A., Halstenson, C.E., Opsahl, J.A., Matzke, G.R., Ellis, C.L., and Keane, W.F., 1987, Uricosuria: A potential mechanism for suprofen nephropathy, Proc. Int. Congr. Nephrol. 10:448a (Abstract).Google Scholar
  549. 544.
    Segasothy, M., Thyaparan, A., Kamal, A., and Sivalingam, S., 1987, Mefenamic acid nephropathy, Nephron 45:156–157.PubMedGoogle Scholar
  550. 545.
    Ciabattoni, G., Boss, A.H., Patrignani, P., Catella, F., Simonetti, B.M. Pierucci, A., Pugliese, F., Filabozzi, P., and Patrono, C., 1987, Effects of sulindac on renal and extrarenal eicosanoid synthesis, Clin. Pharmacol. Ther. 41:380–383.Google Scholar
  551. 546.
    Swainson, C.P., Griffiths, P., and Watson, M.L., 1986, Chronic effects of oral sulindac on renal haemodynamics and hormones in subjects with chronic renal disease, Clin. Sci. 70:243–247.PubMedGoogle Scholar
  552. 547.
    Mistry, C.D., Lote, C.J., Gokal, R., Currie, W.J.C., Vandenburg, M., and Mallick, N.P., 1986, Effects of sulindac on renal function and prostaglandin synthesis in patients with moderate chronic renal insufficiency, Clin. Sci. 70:501–505.PubMedGoogle Scholar
  553. 548.
    Sethi, K., Jain, R., and Malhotra, S., 1987, Effects of long-term sulindac therapy in chronic renal failure, Proc. Int. Congr. Nephrol. 10:33a (Abstract).Google Scholar
  554. 549.
    Whelton, A., Stout, R.L., Drew, H., LaFrance, N., Spilman, P.S., Crocetti, S.S., Hermann, J., Klassen, D., Delgado, F., and Watson, A.J. 1987, A prospective, randomized, cross-over study of the renal effects of ibuprofen, piroxicam, and sulindac in chronic renal impairment, Proc. Int. Congr. Nephrol. 10:38a (Abstract).Google Scholar
  555. 550.
    Quintero, E., Gines, P., Arroyo, V., Rimola, A., Camps, J., Gaya, J., Guevara, A., Rodamilans, M., and Rodes, J., 1986, Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in cirrhosis with ascites, Nephron 42:298–303.PubMedGoogle Scholar
  556. 551.
    Brater, D.C., Anderson, S.A., and Brown-Cartwright, D., 1987, Reversible acute decrease in renal function by NSAIDs in cirrhosis, Am. J. Med. Sci. 294:168–174.PubMedGoogle Scholar
  557. 552.
    Brater, D.C., Brown-Cartwright, D., Anderson, S.A., and Uaamnuichai, M., 1987, Effect of high-dose etodolac on renal function, Clin. Pharmacol. Ther. 42:283–289.PubMedGoogle Scholar
  558. 553.
    Ruilope, L.M., Garcia-Robles, R., Paya, C., Alcazar, J.M., Miravalles, E., Sancho-Rof, J., Rodicio, J., Knox, F.G., and Romero, J. C,. 1986, Effects of long-term treatment with indomethacin on renal function, Hypertension 8:677–684.PubMedGoogle Scholar
  559. 554.
    Nicholls, A.J., Shortland, J.R., and Brown, C.B., 1985, Mefenamic acid nephropthy—A spectrum of renal lesions, Proc. EDTA-ERA 22:991–996.Google Scholar
  560. 555.
    Schneider, P.D., 1986, Nonsteroidal antiinflammatory drugs and acute cortical necrosis, Ann. Intern. Med. 705:303–304.Google Scholar
  561. 556.
    Moss, A.H., Riley, R., Murgo, A., and Skaff, L.A., 1986, Over-the-counter ibuprofen and acute renal failure, Ann. Intern. Med. 105:303.PubMedGoogle Scholar
  562. 557.
    Justiniani, F.R., 1986, Over-the-counter ibuprofen and nephrotic syndrome, Ann. Intern. Med. 105:303.PubMedGoogle Scholar
  563. 558.
    Tolins, J.P. and Seel, P., 1989, Ibuprofen induced interstitial nephritis and the nephrotic syndrome, Nephron (in press).Google Scholar
  564. 559.
    Artinano, M., Etheridge, W.B., Stroehlein, K.B., and Barcenas, C.G., 1986, Progression of minimal-change glomerulopathy to focal glomerulosclerosis in a patient with fenoprofen nephropathy, Am. J. Nephrol. 6:353–357.PubMedGoogle Scholar
  565. 560.
    Alavi, N., Lianos, E.A., Venuto, R.C., Mookerjee, B.K., and Bentzel, C.J., 1986, Reduction of proteinuria by indomethacin in patients with nephrotic syndrome, Am. J. Kidney Dis. 8:397–403.PubMedGoogle Scholar
  566. 561.
    Laurent, J., Belghiti, D., Bruneau, C., and Lagrue, G., 1987, Diclofenac, a nonsteroidal antiinflammatory drug, decreases proteinuria in some glomerular diseases: A controlled study, Am. J. Nephrol. 7:198–202.PubMedGoogle Scholar
  567. 562.
    Netter, P., Bannworth, B., Pere, P., and Nicolas, A., 1987, Clinical pharmacokinetics of Dpenicillamine, Drugs 13:317–333.Google Scholar
  568. 563.
    Ntoso, K.A., Tomaszewski, J.E., Jimenez, S.A., and Neilson, R.G., 1986, Penicillamineinduced rapidly progressive glomerulonephritis in patients with progressive systemic sclerosis: Successful treatment of two patients and a review of the literature, Am. J. Kidney Dis. 8:159–163.PubMedGoogle Scholar
  569. 564.
    Feehally, J., Wheeler, D.C., Mackay, E.H., Oldham, R., and Walls, J., 1987, Recurrent acute renal failure with interstitial nephritis due to D-penicillamine, Renal Failure 10:55–57.PubMedGoogle Scholar
  570. 565.
    Rehan, A. and Johnson, K., 1986, IgM nephropathy associated with penicillamine, Am. J. Nephrol. 6:71–74.PubMedGoogle Scholar
  571. 566.
    Matthey, F., Perrett, D., Greenwood, R.N., and Baker, L.R.I., 1986, The use of D-penicillamine in patients with rheumatoid arthritis underoing hemodialysis, Clin. Nephrol. 25:268–271.PubMedGoogle Scholar
  572. 567.
    Blocka, K.L.N., Paulus, H.E., and Furst, D.E., 1986, Clinical pharmacokinetics of oral and injectable gold compounds, Clin. Pharmacol. 11:133–143.Google Scholar
  573. 568.
    Hall, C.L., Harrison, P.R., McKenzie, J.C., Tribe, C.R., and Mclvor, A., 1987, The natural history of gold nephropathy: A long term study of 21 patients, Proc. Int. Congr. Nephrol. 10:65a (Abstract).Google Scholar
  574. 569.
    Pitts, T.O., Spero, J.A., Bontempo, F.A., and Greenberg, A., 1986, Acute renal failure due to high-grade obstruction following therapy with ε-aminocaproic acid, Am. J. Kidney Dis. 8:441–444.PubMedGoogle Scholar
  575. 570.
    Wilson, C., Azmy, A.F., Beattie, T.J., and Murphy, A.V., 1986, Hypermagnesemia and progression of renal failure associated with renacidin therapy, Clin. Nephrol. 25:266–267.PubMedGoogle Scholar
  576. 571.
    Davis, M.C.E., Jr., Carpenter, Col. J.L., Ognibene, A.J., and McAllister, C.K., 1986, Rifampin-induced acute renal failure, South. Med. J. 79:1012–1015.PubMedGoogle Scholar
  577. 572.
    Murray, A.N., Cassidy, M.J.D., and Templecamp, C., 1987, Rapidly progressive glomerulonephritis associated with rifampicin therapy for pulmonary tuberculosis, Nephron 46: 373–376.PubMedGoogle Scholar
  578. 573.
    Leighton, J.D., Walker, R.J., and Lynn, K.L., 1986, Trimipramine-induced acute renal failure, NZ Med. J. 99:248.Google Scholar
  579. 574.
    Björck, S., Westberg, G., and Svalander, C., 1987, Hydralazine-induced glomerulonephritis: A serious complication to long-term treatment, Proc. Int. Congr. Nephrol. 10:51a (Abstract).Google Scholar
  580. 575.
    Skinner, R. and Ferner, R.E., 1986, Acute renal failure without acute intravascular haemolysis after nomifensine overdosage, Hum. Toxicol. 5:279–280.PubMedGoogle Scholar
  581. 576.
    Addo, E. and Poon-King, T., 1986, Leucocyte suppression in treatment of 72 patients with paraquat poisoning, Lancet 1:1117–1120.PubMedGoogle Scholar
  582. 577.
    Turk, J., Morrell, L., and Avioli, L.V., 1986, Ethylene glycol intoxication, Arch. Intern. Med. 146:1601–1603.PubMedGoogle Scholar
  583. 578.
    Gabow, P.A., Clay, K., Sullivan, J.B., and Lepoff, R., 1986, Organic acids in ethylene glycol intoxication, Ann. Intern. Med. 105:16–20.PubMedGoogle Scholar
  584. 579.
    Weaver, A.N. and Sica, D.A., 1987, Mannitol-induced acute renal failure, Nephron 45:233– 235.Google Scholar
  585. 580.
    Giménez, A. and Mampaso, F., 1986, Characterization of inflammatory cells in drug-induced tubulointerstitial nephritis, Nephron 43:239–240.PubMedGoogle Scholar
  586. 581.
    Boucher, A., Droz, D., Adafer, E., and Noel, L-H., 1986, Characterization of mononuclear cell subsets in renal cellular interstitial infiltrates, Kidney Int. 29:1043–1049.PubMedGoogle Scholar
  587. 582.
    Toll, L.L., Lee, M., and Sharifi, R., 1987, Cefoxitin-induced interstitial nephritis, South. Med. J. 80:274–276.PubMedGoogle Scholar
  588. 583.
    Geller, R.J., Chevalier, R.L., and Spyker, D.A., 1986, Acute amoxicillin nephrotoxicity following an overdose, Clin. Toxicol. 24:175–182.Google Scholar
  589. 584.
    Nolan, C.R., Anger, M.S., and Kelleher, S.P., 1986, Eosinophiluria—A new method of detection and definition of the clinical spectrum, N. Engl. J. Med. 315:1516–1519.PubMedGoogle Scholar
  590. 585.
    Sacks, P. and Fellner, S.K., 1987, Recurrent reversible acute renal failure from amphotericin, Arch. Intern. Med. 147:593–595.PubMedGoogle Scholar
  591. 586.
    Tolins, J.P. and Rai, J.L., 1986, Amphotericin B: Phatophysiology of adverse renal hemodynamic effects in the rat, Clin. Res. 34:558a (Abstract).Google Scholar
  592. 587.
    McCarthy, J.T. and Staats, B.A., 1986, Pulmonary hypertension, hemolytic anemia, and renal failure, Chest 89:608–610.PubMedGoogle Scholar
  593. 588.
    Cantrell, J.E., Phillips, T.M., and Schein, P.S., 1985, Carcinoma-associated hemolytic-uremic syndrome: A complication of mitomycin C chemotherapy, J. Clin. Oncol. 3:723–734.PubMedGoogle Scholar
  594. 589.
    Desablens, B., Fievet, P., Pruna, A., Claisse, J.F., Westeel, P.F., Tolani, M., and Fournier, A., 1986, Hemolytic-uremic syndrome after cancer chemotherapy without mitomycin C, Nephron 42: 343–344.PubMedGoogle Scholar
  595. 590.
    Bertani, T., Cutillo, F., Zoja, C., Broggini, M., and Remuzzi, G., 1986, Tubulointerstitial lesions mediate renal damage in Adriamycin glomerulopathy, Kidney Int. 39:488–496.Google Scholar
  596. 591.
    Mimnaugh, E.G., Trush, M.A., and Gram, T.E., 1986, A possible role for membrane lipid peroxidation in anthracycline nephrotoxicity, Biochem. Pharm. 35:4327–4335.PubMedGoogle Scholar
  597. 592.
    Reid, G.M. and Muther, R.S., 1987, Nitroprusside-induced acute azotemia, Am. J. Nephrol. 7: 313–315.PubMedGoogle Scholar
  598. 593.
    Wright, L.F. and DuVal, W., Jr., 1987, Renal injury associated with laxative abuse, South. Med. J. 80:1304–1306PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1989

Authors and Affiliations

  • William M. Bennett
    • 1
  1. 1.Department of MedicineOregon Health Sciences UniversityPortlandUSA

Personalised recommendations